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All biological life lives under the constant threat of viral infection.  From the 
earliest homo sapiens until now well into the 21st century, the destruction brought on 
human life by viruses has been immense. Combating the viral threat has always required 
a combination of basic science and applied engineering.  Scientific understanding of how 
viruses infect, propagate, and evolve is a pre-requisite for understanding how to go about 
preventing their activity.  Of equal importance is the engineering of applications to take 
advantage of that knowledge to build solutions to the constant threat.  The combination of 
hypothesis driven research and applied biotechnology lead to the first vaccines and the 
process continues to this day as we continue to build better diagnostic tools, safer 
vaccines, and more comprehensive strategies to combat the constant viral threat. Recent 
outbreaks of Ebola, Norovirus, Arenaviruses, novel Influenza strains, and Zika virus 
punctuate the ongoing need for understanding and application.  Continuing in this 
tradition, the work describes both basic science and applied biotechnology approaches to: 
1) understand host-viral evolution patterns in New World Arenaviruses, 2) identify Ebola 
specific antibodies for a diagnostic platform, and 3) characterize the immune profile 
following a Norovirus vaccine in clinical trials.   
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Chapter 1: Introduction 
 
Viruses are a constant threat to human health. They are naturally passed through 
fluids, air, and bodily contact. They infect both wild and domesticated species and some 
of them routinely hop into and through the human population. Viral infection and spread 
is exacerbated by the effects of large human migration movements, humans pushing into 
wildlands, and the general trend towards globalism. There is also the threat of 
bioterrorism using viruses.  In addition to the known threat, more and more new viruses 
are routinely being discovered (Lipkin, 2010), (Datta et al., 2015).  Major outbreaks and 
pandemics are likely to occur in the near future (Wolfe, 2011). 
Combating existing and new viral threats requires both an understanding of how 
they work and the development of tools to combat them.  A fundamental understanding 
of how viruses infect, spread, and evolve is required to inform a plan of action to take 
against viruses. Application of that knowledge leads to to better diagnostic tools and 
vaccines.  
Here I focus on three different viruses which are having major impacts on human 
health.  In this dissertation I describe work that I and others have done on New World 
Arenaviruses, Ebola-Reston Virus and Human Norovirus. These studies investigate 
viruses from both a basic science approach and an applied technology approach. In 
addition to multiple approaches, this work is highly collaborative, combining efforts in 




University of Texas at Austin. In the TfR1-Machupo work (Chapter 2), I utilize a number 
of wet lab and virology techniques to demonstrate the effects the Transferrin Receptor 1 
(TfR1) surface has on New World Arenavirus entry patterns.  This work resulted in a 
collaboration with Eleisha Jackson in Claus Wilke’s lab in which Eleisha was able to 
develop a Rosetta based computational model that was able to accurately predict the 
strength of the binding affinities that I characterized in the lab. In the Ebola work 
(Chapter 3), I work in parallel with a number of researchers at UT to identify novel 
antibodies that bind to the glycoproteins of Ebola.  In that project we use novel Ebola 
VLPs that were designed and built at Rob Davies’ lab at the Texas Biomedical Research 
Institute and we worked with Luminex in Austin, Texas to test our Ebola antibodies in a 
diagnostic assay based on their Magpix bead platform. In my ongoing Norovirus work 
(Chapter 4) I use two new technologies developed in the Georgiou lab to investigate the 
immune response in a donor who participated in a Phase 1 clinical vaccine trial with 
Takeda Pharmaceuticals.   
NEW WORLD ARENAVIRUSES 
  
The first New World Arenavirus zoonotic outbreak occurred in Junín, Argentina 
in 1958 (Agnese, 2007). Over the next fifty years four more New World Arenaviruses 
have infected humans; (Junín - 1958, Machupo - 1963, Guanarito - 1989, Sabia - 1990, 
Charpare – 2003) (Johnson and Wiebenga, 1965), (Delgado et al., 2008), (Salas et al., 




every few years on a regular basis. In humans, viral infection leads to hemorrhagic fever 
and can have lethality rates as high as 30%. (Peters, 2002)   
Small rodents throughout South and Central America carry New World 
Arenaviruses. Transmission from rodent to humans occurs through direct contact and/or 
aerosolization of virions in rodent feces and urine (LeDuc, 1989). Felines can also harbor 
the virus and a rodent-feline-human transmission pathway is likely occurring. Arenavirus 
transmission to humans is likely to increase as humans push further into wilderness areas 
within the host species range.   
The New World Arenavirus phylogeny contains 29 species separated into four 
clades; A, B, C and A/B recombinant.  The five New World Arenaviruses that infect 
humans are found in clade B of the arenavirus phylogeny (Nunberg and York, 2012) 
(Charrel et al., 2011). Clade B arenaviruses are unique in that their mechanism of entry 
into mammalian cells relies on the host encoded Transferrin Receptor 1 (TfR1) 
(Radoshitzky et al., 2007). 
New World Arenaviruses are an emergent public health and bioterrorism threat 
due to their ability to infect humans and cause hemorrhagic fever. These viruses are 
categorized as BSL4, the most dangerous rating due to their lethality and lack to 
treatment options (NIAID website). The arenaviruses are very stable to desiccation, 
making them well-suited for terrorism and easy distribution.  
Currently there are no FDA approved vaccines available for New World 




in South America. Candid 1 is an attenuated Junin strain, the virus was passaged through 
guinea pig, mouse brain and fetal rhesus monkey lung cells (Barrera Oro and McKee, 
1991).  
 
EBOLA VIRUS  
 
The Ebola virus was first identified in a human outbreak in 1976.  Since that time, 
regular outbreaks have occurred. It is an emerging virus and outbreaks have been 
reported periodically at 2-10 year intervals. Outbreaks occur primarily in Africa but other 
locations, including the US have experienced outbreaks of Ebola.  The largest outbreak of 
Ebola was the most recent occurring in 2013-2015. Ebola outbreaks routinely have 
lethality rates of 50% and can be as high as 95% (Peters, 1996). Virus is spread by 
contact with blood or body fluids from infected individuals or animals, and is highly 
infectious.  Due to it high lethality, Ebola virus is a BSL4 category pathogen 
The primary animal reservoir is still unknown however, bats are hypothesized to 
be the reservoir (Leroy et al., 2005), (Amman et al., 2012).  In addition to humans, Ebola 
virus can infect other primates and the virus has decimated gorilla populations in Africa 
(Bermejo et al., 2006).  It has also been determined that Ebola can replicate in swine.  Of 
particular interest is that infected swine are asymptomatic (Marsh et al., 2011) and there 




2009).  It has also been demonstrated that primates can pass Ebola to swine via 
aerosolization, (Weingartl et al., 2012). 
Currently there are no vaccines approved for Ebola virus. However, there are 
candidates in clinical trials.  The latest trial was run during the recent Ebola outbreak in 
West Africa.  The vaccine consists of a replication competent vesicular stomatitis virus 
(VSV)  pseudotyped with the glycoprotein of the Zaire strain of Ebola virus.  In the phase 
1 trail the vaccine was deemed safe and it was shown that trial volunteers were able to 
mount an immune response against the vaccine (Agnandji et al., 2015).  Primate studies 
done with the same vaccine demonstrated that the vaccine was protective against live 
Ebola virus in those animals (Geisbert et al., 2008). 
NOROVIRUS 
 
Norovirus infects a number of species including human, mice, swine, and bovine.   
Norovirus strains are generally considered to be species specific and zooinotic events are  
rare (Mattison et al., 2007).  The virus is typically spread though contaminated bodily 
fluids such as fecal matter and vomit. The transmission route is generally fecal-oral.  
There is also evidence that the virus can be aerosolized as well and presumably could 
lead to infection inhalation or oral uptake (Bonifait et al., 2015). 
 Norovirus is not particularly lethal but it does cause over 50% of the cases 
of gastroenteritis worldwide, and 21 million norovirus infections occur annually in the 




living quarters such as dormitories, cruise ships and military bases.  Retirement home and 
elderly care facilities are particularly vulnerable as elderly patients are much more likely 
to be immunocompromised and develop chronic infections (Karin Bok, 2013). 
 Currently there are no approved vaccines for Norovirus.  A VLP based vaccine 
has undergone phase 1 trials and was demonstrated to be safe and immunogenic however 
it failed to elicit long term protection (Treanor et al., 2014).  One complication for 
developing a Norovirus vaccine is that, much like Influenza, Norovirus evolves quickly.  
This quick evolution is hypothesized to be driven by herd immunity within the human 
population. The process results in a new dominant Norovirus strain approximately every 
2 years (Lindesmith et al., 2011). 
 
SIGNIFICANCE AND HYPOTHESIS 
  
New World Arenaviruses, Ebola virus, and Norovirus all present similar 
challenges.  They have all started infecting humans in the last 70 years. They all have 
animal origins although it is unclear what the animal origins are, particularly for Ebola 
and Norovirus.  New World Arenaviruses and Ebola have regular outbreaks in the human 
population and Norovirus continuously circulates through the human population.  An 
active area of research investigates the process of how a virus undergoes a species 
switching event in which it begins to infect a species that it did not previously infect. 




It is imperative that we gain a better understanding how viruses evolve and switch 
species. Studying past species switching events provides valuable insight into what lead 
causes species switching to occur.  Mechanistic insight will allow us to begin to predict 
what viral mutations can contribute to a species switching event.  Further understanding 
and proper monitoring of viral evolution will lead to the identification of emerging viral 
species switching events and allow for proper action to be taken before a virus can cause 
large amounts of damage to humans or other species.  
Similar to influenza, all three viruses studied here have RNA genomes. Viral 
replication is dependent on an RNA dependent RNA polymerase. The inability of RNA 
dependent RNA polymerases to proofread contributes to a high errors rate in the viral 
replication process. An error rate of ~1 in 10,000 bp occurs in RNA genomes. 
(Steinhauer and Holland, 1986) This high error rate accelerates the number of mutations 
that the virus can sample in evolutionary space and much like the influenza virus allows 
them to rapidly evolve as they explore various fitness landscapes. 
In order for a virus to infect a new species it must have mutations that allow it 
access to spaces that it was formerly prevented in.  For instance, in the case of receptor 
usage, the virus has higher chance of success if it acquires one or more mutations that 
allow it to bind to a receptor in a potential host that it was previously not able to interact 
with. Once this barrier is overcome, low levels of infection can occur and give the 
opportunity for more mutations to arise.  This appears to be the case of the New World 




entry.  Across the mammalian phylogeny, TfR1 has evolved in such a manner that some 
species TfR1’s are permissive to a particular New World Arenavirus, such as Machupo, 
and others are not (Abraham et al., 2010) (Figure 1.1).  
 
Figure 1.1 - Host Receptor Dynamics 
The New World Arenavirus glycoproteins are compatible with receptors of some species 
and not others.  Depicted here, the blue glycoprotein on the virus is able to bind the blue 
receptor on species A. Upon successful binding the virus can then be taken up by the cell. 
The virus is unable to enter Species B because it is unable to bind and interact with the 
Species B receptor, depicted in orange.  Amino acid differences between the Species A 
and Species B receptor at the viral glycoprotein binding site contribute to whether the 
receptor is permissive to virus entry or a barrier to the virus.  In order for the virus to gain 
entry through the Species B receptor, it must acquire mutations that allow to bind the 
receptor long enough for viral uptake to take place.  
 
The focus of the work described here will remain primarily focused on the host-
virus interactions that take place at the receptor binding interface; the reason for this is 




event. However, it should be noted that in addition to initial entry mediated by the viral 
glycoprotein, mutations that favor replication in the new species are selected for 
throughout the viral genome (Meyerson and Sawyer, 2011). This creates a more fit virus 
that overtime leads to a full species switching event in which the new virus has sufficient 
ability to successfully infect, replicate, avoid in innate immunes response, and transmit 
through the new host species. (Sawyer and Elde, 2012) 
 The concept of mutations being introduced to initiate a species switching event 
suggests two unique possibilities.  The first is that these potential mutations arise by 
chance and are simply selected for when the virus with the rare mutations happens to 
interact with the cells of the new host species.  The second is that there may be selective 
pressure creating mutations at the virus interface that interacts with the host receptor.  
The hypothesis addressed here is that pressure put upon the virus at the receptor binding 
site by the host immune mediated antibody response is selecting for mutations that, in 
addition to evading the immune response, confer the virus with a set of mutations that 






Figure 1.2 – Species Switching Hypothesis 
During a viral infection, the host adaptive immune response produces antibodies that bind 
the virus, some of which directly bind the receptor bind site on the viral glycoprotein 
surface.  The antibody block on the glycoprotein inhibits viral entry through the receptor 
and blocks viral infection.  This block puts pressure on the viral genome to select for 
amino acid changes in the viral glycoprotein that prevent the antibodies from binding the 
receptor binding site on the virus.  The overall hypothesis this work aims to test is that 
these mutations on the viral glycoprotein that block antibody binding are also leading the 
virus to interact with receptors of other species that it was previously unable to interact 
with. 
 
 In addition to the innate immune response, a spreading viral infection is attacked 
by the host adaptive immune response and in particular the antibodies that bind to the 
virus glycoproteins or viral capsid proteins.  An effective way for antibodies to inhibit 
viral infections and spread is for the antibody to bind the viral glycoprotein or capsid 
protein at the interface that the virus uses to bind the host receptor protein.  This is also a 
common strategy for developing vaccines.  Chapter 4 discusses further work 




the virus from interacting with the sugar groups required for viral entry and infection. 
(Treanor et al., 2014).  Blocking the receptor site puts great pressure on the virus. It is 
hypothesized that Norovirus evolution is driven by the adaptive immune response. 
(Lindesmith et al., 2012) Mutations that arise in response to evading antibody binding to 
the receptor binding site will also modify how the virus binds the host receptor and 
potentially the receptors or other species that it does not infect thereby priming it for a 
species switching event. 
Testing this hypothesis requires three experimental approaches. To test it requires 
host-virus system that can accurately assay the difference between a permissive and non-
permissive receptor system.  Chapter 2 works towards these goals and describes 
numerous successes demonstrating receptor permissiveness and non-permissiveness. The 
second aspect is identifying one or preferably more antibodies that can block viral entry 
by binding at the binding site. 
Antibody discovery historically has been done using hybridoma technology. 
However this approach is time consuming, very inefficient with respect to how many 
antibodies can be isolated from it (Pirofski et al., 1990), and it also suffers from a 
multiple light chain problem (Zack et al., 1995), meaning that you may be dealing with 
an antibody that was not selected by the immune system.  Additionally, non-natural 
antibodies are less than ideal when testing a hypothesis that is based on a natural immune 
response. Other antibody discovery technologies rely on constructing large libraries of 




1985), (Boder and Wittrup, 1997). These both suffer from the same problems as the 
hybridoma methodology in that the selected antibodies are not actual representatives 
from the immune response and are typically screened from large synthetic libraries or 
libraries derived from the heavy and light chain sequences pulled from pools of B-cells.  
The Georgiou lab has developed a technology, VH:VL pairing that allows for the 
isolation and sequencing of immune system derived antibodies. VH:VL pairing is 
described in Chapter 3 and 4, and elsewhere. (DeKosky et al., 2013), (McDaniel et al., 
2016) Antibodies against both Ebola glycoprotein and Norovirus capsid protein were 
identified using this approach. However, it was found that anti-Ebola antibodies 
described in Chapter 3 and elsewhere (Wang et al., 2015) did not block viral entry when 
tested and while useful for diagnostic and research purposes they are not sufficient to test 
the hypothesis presented here.  Chapter 4 describes work to identify anti-Norovirus 
antibodies from an immune response that was demonstrated to contain antibodies that 
block viral interactions with host receptors.  Identification of these blocking antibodies 
provides an ideal antibody to test if antibody escape by viruses contributes to their ability 
to switch species. 
The final aspect of testing this hypothesis requires a viral evolution system in the 
lab that can reliably be used to select for viral variants that can switch species effectively 
and propagate those viruses. Ultimately the approach was unsuccessful and a proper 
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Chapter 2:  Computational and functional analysis of the GP1–TfR1 interface 




Viruses need to enter cells of a host organism in order to make more copies of 
themselves. Many viruses interact with protein receptors found on the surface of host 
cells in order to gain entry into those cells. Like all proteins, these host receptors can vary 
in sequence from species to species. Viruses tend to be acutely adapted to use the 
receptor of one species, with the unintentional consequence of being poorly adapted to 
the receptor encoded by related species. For instance, HIV-1 can enter cells using the 
human CD4 receptor but not the CD4 of most other primate species (Humes et al., 2012), 
(Meyerson et al., 2015). A key event in the emergence of new diseases often involves 
evolution of the viral genome in a way that renders it compatible with the receptor 
ortholog encoded by a new host species (reviewed in (de Graaf and Fouchier, 2014), 
(Gerlier, 2011), (Graham and Baric, 2010), (Choe et al., 2011),  (Parrish and 
Kawaoka, 2005), (Parrish et al., 2008). The identification of host genes that impact viral 
replication in a species-specific fashion is the foundation for understanding why viruses 
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infect the species that they do, and essential for understanding the genetic changes that 
viruses must acquire to infiltrate new species.  
The New World arenaviruses, which infect Central and South American rodent 
species, present an ongoing public health threat. Five different viruses in this family are 
zoonotic, meaning that they are transmitted from their rodent host species to humans 
(Figure 2.1) (Delgado et al., 2008), (Peters, 2002). Infection in humans can lead to 
hemorrhagic fever and individual outbreaks can have lethality rates as high as 30% 
(Borio et al., 2002) . The New World arenavirus phylogeny has four major clades: A, B, 
A/B recombinant, and C, with all zoonotic arenaviruses residing in clade B (Charrel et 
al., 2011). Transmission to humans likely occurs through direct contact with rodents and 
through inhalation of aerosolized virions excreted in rodent feces and urine (LeDuc, 
1989). Currently, the geographic ranges of the rodent species that carry these viruses are 
constrained by specific habitat requirements. However, should arenaviruses ever spread 
to common species such as the house mouse (Mus musculus) or the brown rat (Rattus 





Figure 2.1. New World arenaviruses and the species that they infect.  
A phylogeny of clade B New World arenaviruses is shown (adapted from (Charrel et al., 
2011)). The rodent species that are known to be endemically infected with each virus are 
listed to the right, along with an indication of the country where the rodent/virus pair is 
found. Asterisks identify zoonotic viruses known to infect humans. 
 
The clade B arenaviruses enter host cells via the host-encoded Transferrin 
Receptor 1 (TfR1) (Radoshitzky et al., 2007). The primary function of TfR1 is to mediate 
the uptake of iron-loaded transferrin, and to a lesser extent H-ferritin (Li et al., 2010), 
from the serum (reviewed in (Aisen, 2004)). The interaction of arenaviruses with TfR1 is 
mediated by the virus surface spike, or glycoprotein (GP). The viral spike consists of a 
trimer of GP1/GP2 dimers and interaction with TfR1 involves GP1 (reviewed in (Rojek 
and Kunz, 2008)). A co-crystal structure demonstrating the interaction between human 




(Abraham et al., 2010). Each of the clade B arenaviruses have distinct patterns of 
compatibility with the TfR1s encoded by various mammalian species (Abraham et al., 
2010), (Radoshitzky et al., 2008), (V. K. Martin et al., 2010), (Abraham et al., 2009), 
(Flanagan et al., 2008). For instance, Machupo virus enters cells through the TfR1 of its 
rodent host species, Calomys callosus, but not through the TfR1 of the closely-related 
Junin virus host species, Calomys musculinus (Radoshitzky et al., 2008). In addition, 
human TfR1 is a functional receptor only for the five zoonotic New World arenaviruses, 
but not other New World arenaviruses (Radoshitzky et al., 2007), (Flanagan et al., 2008), 
(Helguera et al., 2012). The TfR1 of brown rats and house mice have been found to be 
non-functional entry receptors for all clade B arenaviruses tested (Radoshitzky et al., 
2008), (Abraham et al., 2009), (Flanagan et al., 2008), (Cuevas et al., 2011) in line with 
the observation that these species have never been found to harbor arenaviruses in nature. 
Two other families of animal viruses, carnivore parvoviruses and rodent MMTV-like 
retroviruses, also use TfR1 to enter cells (Ross et al., 2002), (Parker et al., 2001). For all 
of the virus families that use TfR1, existing evidence suggests that the ability to enter 
cells through the TfR1 ortholog of a particular species is a necessary criterion for 
infection in the wild, and that viral adaptation is often required to utilize the TfR1 of the 
new species, (Parrish and Kawaoka, 2005), (Stucker et al., 2012), (Demogines et al., 





Recently, we have demonstrated that much of the sequence variability in TfR1 
between different rodent and carnivore species is the result of host-virus evolutionary 
arms races (Demogines et al., 2013), (Kaelber et al., 2012). Specifically, TFR1 has 
experienced repeated rounds of natural selection for mutations that reduce its 
functionality as a virus entry receptor. In turn, the viruses that use TfR1 have been 
counter-selected in the gene encoding their surface spike for mutations that re-establish 
cellular entry through new receptor variants (Parrish and Kawaoka, 2005), (Stucker et al., 
2012). In arms races such as this, codon positions where mutations most potently alter the 
virus-receptor physical interaction, without affecting protein folding or function, are 
subject to the strongest positive selection and thus evolve rapidly (Meyerson and Sawyer, 
2011), (Daugherty and Malik, 2012). Arms race dynamics can be detected by identifying 
codons that have a significantly higher number of non-synonymous substitutions than 
would be expected under a model of neutral or purifying selection (Meyerson and 
Sawyer, 2011), (Daugherty and Malik, 2012), (Sironi et al., 2015). We previously 
performed positive selection analysis on an alignment of TFR1 sequences from various 
rodent species, and found three codons (corresponding to human TfR1 residue positions 
205, 209, and 215) near the Machupo binding region that have undergone recurrent 
positive selection during the speciation of rodents and are therefore evolving at an 
unusually high rate, (Demogines et al., 2013). However, the effect of mutations at these 
sites in TfR1 have not been tested. Recently, positive selection analysis has proven 




govern interactions with viruses (Demogines et al., 2013), (Kaelber et al., 2012), 
(Demogines et al., 2012), (Meyerson et al., 2014), but it remains to be explored whether 
positive selection analysis could add value to our current understanding of the arenavirus-
binding surface of TfR1 and the species-specificity of this interaction. 
 
Here we show that TfR1 from the common brown rat functions as a receptor for 
Machupo virus if residues from the Machupo virus host species, Calomys callosus, are 
substituted into the small protein motif identified by positive selection analysis. We also 
show that the specific TfR1 residues that dictate Machupo entry are not the same residues 
that govern entry by Chapare and Sabia arenaviruses. Moreover, a human SNP in this 
region, L212V, which has previously been shown to make human TfR1 a worse receptor 
for Machupo virus entry (Demogines et al., 2013), makes it a better receptor for the Junin 
and Sabia arenaviruses. These findings suggest the potential for evolutionary trade-offs, 
where selection for resistance for one virus could make humans or rodents susceptible to 
other arenaviruses in nature. In all of these experiments, we show that the strength of 
binding affinity between the virus and TfR1 correlates to cellular entry of the virus. 
Based on this, we develop a structural model for assessing the relative energy of binding 
of Machupo GP1 to TfR1 variants. This model is based on homology modeling of TfR1 
variants and subsequent rigid-body docking to Machupo GP1. Binding energies between 
modeled TfR1 variants and Machupo GP1 are calculated using the Rosetta interface 




binding-energy predictions made by our model show good agreement with the functional 
results obtained in this study and others. Our results suggest that a combination of 
positive selection analysis, structural modeling, and experimental verification may 
provide an efficient approach for screening and assessing potential spillover risks of 
viruses circulating in animal populations. 
MATERIALS AND METHODS   
 
Cells and Plasmids.  
Human embryonic kidney 293T cells (ATCC) and canine osteosarcoma D17 
(ATCC) were maintained in Dulbecco modified Eagle's medium (Cellgro) supplemented 
with 10% fetal bovine serum (Gibco), 100 units ml−1 penicillin, 100 µg ml−1streptomycin, 
and 2 mM L-glutamine (Cellgro). Human, Calomys callosus, and Rattus norvegicus TfR1 
with a C-terminal FLAG tag were PCR amplified from pcDNA3.1+ vectors (Radoshitzky 
et al., 2008) and cloned into the Gateway entry vector pCR8 using the pCR8/GW/TOPO 
TA Cloning Kit (Invitrogen). The following primers were used to amplify TfR1 for TA 
cloning: 5ʹ′-TTAATACGACTCACTATAGGG-3ʹ′ and 5ʹ′-
TAGAAGGCACAGTCGAGGC-3.ʹ′ Gateway LR recombination (Invitrogen) was 
performed to transfer TFR1 genes from pCR8 into the entry site in a Gateway-converted 
LPCX retroviral vector. Site-directed mutagenesis of the Rat TfR1 plasmid was 
performed to create the rat-short TFR1 mutant using the QuikChange Site-Directed 







TTTTGAG, and rat-long TfR1 mutant using primers: 5’- 
GGTGACCATAAATGCAAGTAATGGCGTATACCTATTGGAGAGTCCTGAGGGT
TATGTGGC and 3’- 
CCTCAGGACTCTCCAATAGGTATACGCCATTACTTGCATTTATGGTCACCAAG
TTTTGAG. Site-directed mutagenesis was also performed on human TfR1 to introduce 
the L212V mutation (Demogines et al., 2013). Plasmids encoding Machupo (Carvallo 
strain) and Junin (MC2 strain) GP have been described previously (Radoshitzky et al., 
2007). Sabia and Chapare GP sequences, NCBI accession numbers YP_089665 and 
YP_001816782 respectively, in pCAGGS were a gift from Hyeryun Choe. 
 
Generation of Stable Cell Lines   
The LPCX:TFR1 retroviral vectors described above were packaged into virions in 
293T cells by co-transfecting them along with pC-VSV-G (a gift from Hyeryun Choe) 
and the NB-MLV gag-pol packaging plasmid pCS2-mGP (Yamashita and Emerman, 
2004) using TransIT-293 (Mirus). Two days later, supernatants containing virions were 
collected, filtered through 0.22 µm filters, and used to infect D17 cells. 1 mL of D17 cells 
at a concentration of 50,000 cells/mL were plated in 12-well plates 24 hours prior to 




of media containing 125-1000 µL of virus and polybrene at a final concentration of 5 
µg/mL. Following infection cells were spinoculated at 1200g for 90 minutes at 30oC. 24 
hours after infection, media was removed and fresh media containing 1.0 
µg/mL puromycin was added to select for transduced cells. All TfR1 receptors tested 
have a C-terminal FLAG tag that is extracellular when the receptor is at the cell surface 
(Abraham et al., 2009); expression of TfR1 proteins was detected in live cells by flow 




Entry Assays   
Pseudoviruses used for entry assays (arenavirus GP-pseudotyped MLV 
recombinant retroviruses) were packaged in 293T cells. TransIT-293 (Mirus) was used to 
co-transfect the GFP-encoding transfer vector pQCXIX (BD Biosciences) along with 
plasmids encoding MLV Gag-Pol and arenavirus GP. After 48 hours, supernatants 
containing viruses were harvested, filtered with 0.22 µm filters, aliquoted, and frozen at 
−80°C. For entry assays, cell lines stably expressing wildtype and mutant TfR1s were 
plated at a concentration of 1×105 cells per well in 24-well plates and, after 24 hours, 
infected with pseudotyped virus along with polybrene at a final concentration of 5 
µg/mL. The plates were spinoculated with centrifugation at 1200g for 90 minutes at 




replaced. Two days post-infection, cells were trypsinized, treated with 1% 
paraformaldehyde for 1 hour and labeled using a FLAG antibody conjugated with 
Allophycocyanin (APC; Abcam, catalog ab72569) to ascertain TfR1 expression. Cells 
were analyzed by flow cytometry. Analysis of flow cytometry data was performed using 
FlowJo 8.8.6 (TreeStar Inc). Cells were gated for live populations and data for 10,000 
cells was collected for analysis. For each experiment, cell populations were further gated 
to represent equivalent MFI for each cell line. This population of cells expressing 
equivalent amounts of TfR1 was scored for GFP expression (viral entry). Where TfR1 
expression is reported, it is reported as the mean fluorescence intensity (MFI) in the 
analyzed population. 
 
Soluble Protein Expression   
Soluble TfR1s (amino acid positions 117-760 in the human TfR1 numbering 
scheme) were amplified with a 3’ primer that introduces a histidine tag and cloned into 










soluble portion which was then joined by PCR to a geneblock (IDT) containing the 
human preprolactin signal sequence (residues 1-34), 
CCGCCACCATGAACATCAAAGGATCGCCATGGAAAGGGTCCCTCCTGCTGCT
GCTGGTGTCAAACCTGCTCCTGTGCCAGAGCGTGGCCCCCTTGCCCATCTGTC
CCGGCCCTGCAGCACGTCGC, using the 5’ primer – 
CCGCCACCATGAACATCAAAGGATCGCCATG, and the same 3’ primer as listed 
above. The product of this reaction was TOPO-TA cloned into pCR8 (Invitrogen) and 
then Gateway cloned (Invitrogen) into the mammalian expression vector pLPCX. 
Plasmids were purified via Midi or Maxi Prep purification (Qiagen). For each TfR1, 
Expi293F cells (LifeTechnologies) were transfected and incubated for 7 days according 
to the manufacturer’s protocol. A pCDM8 plasmid encoding Machupo virus GP1 fused to 
the Fc domain of human immunoglobulin (IgG1) protein was received from Dr. Sheli 
Radoshitzky (Radoshitzky et al., 2007). This fusion protein was expressed in Expi293F 
cells according to the manufacturer’s protocol. 
 
Soluble TfR1 and Machupo Virus GP Purification  
Supernatant was collected following TfR1 production in Expi293F cells and 
centrifuged for 20 minutes at 4,000 rcf to clear cellular debris.  Following centrifugation, 
the supernatant was passed through a 0.45 µm and then a 0.22 µm filter. An equivalent 
volume of binding buffer was added (10 mM imidazole, 50 mM NaH2PO4, 300 mM 




purification resin, Roche).  After incubation the bead-supernatant slurry was passed 
through 5 mL gravity flow columns (Thermo) two times.  The column was washed with 
10 mL of wash buffer (20 mM imidazole, 50 mM NaH2PO4, 300 mM NaCl). TfR1 was 
eluted from the column with elution buffer (250 mM imidazole, 50 mM NaH2PO4, 300 
mM NaCl).  Elution fractions containing TfR1 were pooled, concentrated and buffer 
exchanged with TfR1 buffer (100 mM NaCl, 100 mM KCl, 5 mM KH2P04, pH 6.7) using 
Amicon ultra 100 kilodalton (kDa) filter units (Millipore) to capture fully formed TfR1 
dimer. Samples were flash frozen for storage.  Purified protein was analyzed by boiling 
for 10 minutes in protein loading buffer with 5% beta mercaptoethanol and resolved on 4-
20% SDS-PAGE gels (NuSep). Gel was stained with Gel-Code Blue (Life Technologies). 
For the soluble Machupo GP1-Fc, following transfection, the cellular supernatant 
containing expressed and secreted protein was centrifuged for 20 minutes at 3,000 rcf at 
4°C to clear cellular debris. The supernatant was passed through 0.45 µm filters and then 
0.22 µm filters. 1 mL of Protein A bead slurry (Thermo) was equilibrated by washing 3 
times with 2 mL of PBS, pH 7.4.  Filtered supernatant was incubated with equilibrated 
beads at 4°C on an overhead rotator overnight. Following binding, the bead-supernatant 
mix was passed through a 5 mL gravity flow column (Thermo).  The column was washed 
with 15 mL wash buffer (PBS pH 7.4 + 0.5 M NaCl), and subsequently washed with 15 
mL PBS pH7.4. Machupo GP1-Fc was eluted with elution buffer (PBS pH 7.4 + 3.0 
MgCl) in 1 mL fractions. Fractions containing protein, as determined by absorbance 




pooled.  Sample was buffer exchanged into PBS pH 7.4 to reduce MgCl concentration to 




50 µL of TfR1 at 4 µg/mL per well was incubated in PBS overnight at 4oC to bind 
the protein to the ELISA plate.  Following binding, wells were washed and blocked with 
5% milk in PBS for 2 hours at room temperature. Wells were incubated with Machupo 
GP1-Fc in PBS for 1 hour at room temperature. Wells were washed and incubated with 
1:2000 HRP-conjugated goat antibody raised against Human Fc (Jackson 
ImmunoResearch). Wells were washed and 50 µL of 1-Step Ultra TMB-ELISA Substrate 
Solution (TMB; Thermo Scientific Pierce) was added to the wells and incubated for 
approximately 15 min. The reaction was quenched with 2M H2SO4 and the plate was read 
at 450 nm. Curves were fit using 4 parameter non-linear regression. For the human 
transferrin-TfR1 interaction, transferrin-HRP(Jackson ImmunoResearch) in PBS was 
incubated with 1 mM FeCl(III) for 1 hour at room temperature to load the transferrin with 
iron. The iron-loaded transferrin-HRP was added to the ELISA wells and incubated at 
room temp for 1-hour. Wells were washed and 50 µL of TMB substrate was added to the 
wells and incubated for approximately 15 min.  The reaction was quenched with 2 M 
H2SO4 and the plate was read at 450 nm. Curves were fit using 4 parameter non-linear 




+ ((Min-Max)/(1+(X/EC50)^HillSlope)).  To ensure accuracy, curves were also fit using 
the hyperbola equation: Y = Max + (min-max)/(1+X/Kd)  
 
Structural Homology Modeling and Docking  
We assessed binding affinity in the TfR1–Machupo virus GP1 interface 
computationally using a strategy of homology modeling and docking. In brief, we first 
generated homology models of the TfR1–GP1 complex, using the software MODELLER 
(Eswar et al., 2006), (Webb and Sali, 2014) and the published co-crystal structure for 
human TfR1–Machupo GP1 (Abraham et al., 2010). We then refined these models using 
RosettaDock (Chaudhury et al., 2011). We modeled the TfR1 of house mouse, brown rat, 
Calomys callosus, and human, as well as various mutants of these receptors: rat-short, 
rat-long, mouse-human, and human L212V. Our starting point for homology modeling 
was the crystal structure for the human TfR1–Machupo GP1 (PDB Code: 3KAS), 
(Abraham et al., 2010), which we cleaned by removing all atoms that did not belong to 
amino acids. We then made a multiple sequence alignment using the TfR1s of rat, mouse, 
human and C. callosus using the software MAFFT. We gave the aligned sequences of the 
target TfR1 and the human TfR1 to MODELLER as the input alignment for modeling.  
Next, we made 100 models, using the basic MODELLER homology-modeling protocol. 
We then used the loop modeling protocol to re-model the loops for each modeled mutant 
structure.  We next took each of these 100 modeled complexes and re-docked them in 




consisted of two steps: prepackaging of the side chains and the actual docking. Modeling 
parameters were as follows: For prepackaging, we used the docking prepack protocol in 
Rosetta with the following flags:-database /path/to/rosetta/database; -l pdb_list.txt #List 
of structures to prepack; -docking:partners A_B; -ex1; -ex2aro, -use_input_sc; -
out:file:fullatom; -out:path:pdb ./output_pdbs/. For docking, we used the RosettaDock 
docking protocol with the following flags:-database /path/to/rosetta/database; -l 
pdb_list.txt #List of prepacked structures; -partners A_B; -dock_pert 3 8; -spin, -ex1; -
ex2aro; -use_input_sc ; -nstruct 100; -out:file:scorefile 
human_MACV_GP1_docking.fasc #Name of the output scorefile; -out:path:pdb 
./output_pdbs/ #Path to output directory for pdbs. Next, we performed a step to refine the 
docked orientation of the Machupo GP1 relative to the new TfR1. For each input 
structure obtained from MODELLER, we generated 100 docked complexes, for a total of 
100*100 = 10,000 docked complexes for each modeled TfR1. We took the models with 
the best RosettaDock interface scores to be our representative structures for each modeled 
complex. Lower interface scores indicate tighter binding affinity. Our complete 








Signatures of positive selection in TFR1 refine mapping of the species-specific 
determinants of Machupo virus entry. 
 
A small motif on TfR1 responsible for species-specific interactions with Machupo 
virus was previously defined by genetic mapping studies. Radoshitzky and colleagues 
mapped this region using the TFR1 from house mouse (Mus musculus), which does not 
encode a functional receptor for Machupo virus. They substituted into this gene motifs 
from the human TFR1, which does encode a receptor for Machupo virus, and showed that 
a 5 amino acid motif from human TfR1 (positions R208-L212; blue type in Figure 2A) 
conferred a partial increase in Machupo virus entry (Radoshitzky et al., 2008). (For 
simplicity, all TfR1 coordinates herein refer to the human TfR1 numbering.) The co-
crystal structure between Machupo virus GP1 and human TfR1 shows that these residues 
lie predominantly on a beta strand of TfR1 (brown residues in Figure 2.2B) in a binding 
interface where multiple motifs contribute to inter-molecular interactions (Abraham et al., 
2010). Of the three residue positions that we previously identified to be under positive 
selection, one (residue 209) falls in this region and two more lie just outside of this region 
(residues 205 and 215, yellow highlight in Figure 2.2A) (Demogines et al., 2013). Based 
on this, we hypothesized that the species-specificity of TfR1 for virus entry might be 











Figure 2.2. An extended region of TfR1 determines species-specificity of Machupo virus 
entry. 
 
A. An alignment of one portion of the TfR1 apical domain is shown for host and non-host 
species. The amino acid numbering corresponds to human TfR1. The three residues 
experiencing recurrent positive selection, as previously defined (Demogines et al., 2013), 
are highlighted in yellow. These residue positions are in the arenavirus binding region of 
TfR1, and are not known to be important for the interaction between TfR1 and other 
viruses that use this receptor. In blue type, a strategy is summarized that was previously 
used to map the Machupo-binding interface on TfR1 (Radoshitzky et al., 2008). In that 
previous work, this region was swapped from the human TfR1 (RLVYL) into the house 
mouse (M. musculus) TfR1, replacing the corresponding 4-residues (NLDP). In the 
present work, residues in the C. callosus TfR1 were swapped into the rat TfR1 to create 
the rat-short (red type) and rat-long (red plus green type) chimeric TfR1 shown in the 
bottom two lines. B. The co-crystal structure shows the interaction between Machupo 
virus GP1 (blue) and the human TfR1 apical domain (grey) (PDB: 3KAS) (Abraham et 
al., 2010). The residue positions mutated in the rat-short TfR1 chimera are shown in 
brown. The residues positions mutated in the rat-long chimera are shown in green and 
brown. C. Canine D17 cells were transduced to stably express the wild type and chimeric 
TfR1s with C-terminal FLAG tags. Cells were infected with increasing volumes of 
Machupo pseudovirus (GFP-encoding retrovirus pseudotyped with Machupo virus 
glycoprotein (GP)). Cells were monitored for GFP expression to determine the 
percentage of infected cells.  Error bars indicate standard deviation of three technical 
replicates. Experiment was performed 3 times with similar results seen in all experiments, 
graph represents data from one experiment. A t-test was performed to determine if 
differences between mean values were statistically significant, * <1e-8. Cell surface 
expression of TfR1 was monitored with a FLAG antibody via flow cytometry (inset) 
concurrently with measurement of GFP signal. Expression is given as mean fluorescent 
intensity (MFI). D. A Coomasie-stained SDS page gel shows purified Machupo virus 
GP1 fused to the human IgG1 Fc fragment. E. Coomasie-stained SDS page gels show the 
five purified TfR1 proteins. F.  ELISA comparing the relative binding affinities of 
Machupo GP1 to each of the purified TfR1. Purified TfR1 was bound to wells, and then 
GP1 was incubated at decreasing concentrations to determine the relative binding 
affinities. Error bars indicate standard deviation of three technical replicates. Experiment 
was performed 2 times with similar results seen in both experiments, graph represents 






To test this hypothesis, we examined the TfR1 from the brown rat (Rattus 
norvegicus), which does not function as a receptor for Machupo virus.  We focused on 
the brown rat instead of house mouse because house mouse TfR1 has a variant amino 
acid at position 348 that is not shared by most other rodent TfR1s, or by the human TfR1, 
but which has also been shown to participate in the interaction with Machupo virus 
(Abraham et al., 2010), (Radoshitzky et al., 2008). We used the TfR1 from the Machupo 
virus rodent host, Calomys callosus, as our permissive control TfR1. We created two 
chimeric TfR1’s in which we swapped residues from the permissive C. callosus TfR1 
into the non-permissive rat TfR1 background.  In the first chimera, termed rat-short, we 
replaced five amino acid residues in rat TfR1 (SNIDP) to their respective C. callosus 
residues (NGVYL; red type in Figure 2.2A). This clone is structurally similar to the 
mouse-human TfR1 swap previously described, in that we swapped 5 amino acids 
including and upstream of the “L” or “P” at position 212. In the second chimera, termed 
rat-long, we mutated the rat amino acid residues (SGSNIDPVEA) corresponding to 
human positions 205-215 to their respective C. callosus TfR1 residues (ASNGVYLLES; 
red and green type in Figure 2.2A). This chimera thus contains the entire stretch of C. 
callosus TfR1 encompassing the three positions that have been targeted by positive 
selection. (This region is 11 amino acids long in human TfR1 and 10 amino acids long in 
rodent TfR1.) Stable cell lines expressing each TfR1 were established in canine 
osteosarcoma cells (D17) so that virus entry assays could be performed.  D17 cells were 




et al., 2008), (Abraham et al., 2009), although modest amounts of background entry are 
observed for some viruses ((Flanagan et al., 2008) and demonstrated herein). All TfR1 
receptors were fused to a C-terminal FLAG tag that is localized extracellularly when the 
receptor is embedded in the cellular membrane, allowing receptor expression at the cell 
surface to be detected in live cells by flow cytometry using a FLAG antibody (see 
methods) (Figure 2.2C, inset).  
 
Pseudoviruses were used to test arenavirus entry into these cells. Specifically, 
Machupo virus glycoprotein (GP) was pseudotyped onto murine leukemia virus (MLV) 
particles carrying a green fluorescent protein (GFP) gene. Upon virus entry and infection 
of the cell, the retroviral machinery in the MLV virion drives integration of the GFP gene 
into the cellular (D17) genome. To assess entry via different versions of TfR1, the D17-
TfR1 cell lines were infected with increasing amounts of Machupo pseudovirus and 
fluorescent cells expressing the GFP reporter were counted by flow cytometry two days 
post infection. As expected, the TfR1 of the natural Machupo host species, C. callosus, 
supported high levels of viral entry mediated by the Machupo GP (Figure 2.2C). As was 
seen in the mouse-human TfR1 chimera (Radoshitzky et al., 2008), the rat-short TfR1 
chimera permitted a moderate amount of entry, much greater than rat TfR1, confirming 
that the five amino acid positions introduced from the C. callosus TfR1 were partially 
responsible for Machupo GP mediated entry. The rat-long mutant, whose design was 




to the C. callosus TfR1, indicating that the species-identity of residues in this small 10 
amino acid region more completely defines Machupo virus entry through the TfR1 of 
different species. However, in some contexts other amino acids such as position 348 may 
also play a role (Abraham et al., 2010), (Radoshitzky et al., 2008).  
 
To determine whether or not these mutations alter binding affinity between the 
virus and rat TfR1, we purified a portion of the Machupo virus GP1 (residues 79–248) 
fused to the Fc domain of human IgG1 (Figure 2.2D), as was described previously 
(Radoshitzky et al., 2008). We also purified soluble TfR1 (see methods) representing rat 
as well as the rat-short and rat-long TfR1 variants (Figure 2.2E).  Despite repeated 
attempts, we were unable to express and purify the C. callosus TfR1.  Instead, we 
purified human TfR1 as a positive control, since Machupo virus can also use this receptor 
(Radoshitzky et al., 2007). Each TfR1 was coated onto an ELISA plate, and purified 
Machupo virus GP1-Fc was added at decreasing concentrations. Rat TfR1 did not bind 
GP1 at any concentrations tested (Figure 2.2F). The rat-short TfR1 showed moderate 
binding to GP1 with an EC50 value of 412 + 33 nM, while both rat-long TfR1 and human 
TfR1 bound much tighter to GP1 with EC50 values of 2.37 + 0.18 nM and 2.81 + 0.12 
nM, respectively. Therefore, protein-protein interaction affinities between arenavirus GP 
and TfR1 correlate with cellular entry, as shown here and previously (Abraham et al., 
2010), (Radoshitzky et al., 2008), (Abraham et al., 2009), (Flanagan et al., 2008), 





Virus-specific effects on cellular entry through TfR1 
 
Residues 205-215 in TfR1 interact, in part, with loop 10 in the Machupo virus 
GP1 (Abraham et al., 2010). As has been previously noted, that loop and surrounding 
sequence (colored light pink in Figure 2.3A) is substantially shorter in length in the GP1 
of other arenaviruses (Abraham et al., 2010). Based on this observation, we hypothesized 
that other New World arenaviruses may have unique contact orientations on TfR1.  
 
To analyze how these structurally different arenavirus GP1s interact with TfR1, 
we examined our rat-short and rat-long TfR1 for their ability to support entry of another 
arenavirus.  We pseudotyped MLV-based virions with the GP from Sabia virus, a 
zoonotic virus that is highly diverged from Machupo, both phylogenetically (Figure 2.1) 
and in the sequence of loop 10 (Figure 2.3B). We again observed that these substitutions 
into rat TfR1 created a functional receptor for the arenavirus (Figure 2.3C). However, in 
contrast to what we observed with Machupo virus, we found that both rat-short and rat-
long TfR1 supported equal levels of entry of Sabia virus. So, residues outside of the 
previously defined region of TfR1 matter for host species compatibility, but to different 






























Figure 2.3. Virus-specific effects on entry through TfR1.  
 
A. The Chapare virus GP1 (blue) was homology modeled on the Machupo virus GP1 
crystal structure (magenta; PDB 3KAS). The Machupo virus GP1 loop 10 and 
surrounding residues are shown in light pink, and are absent in the Chapare virus GP1. 
Similar results were seen with Sabia and Junin models (not shown). B. An alignment 
illustrates the C-terminal region of GP1 from Machupo, Junin, Sabia, Chapare, and 
Guanarito arenaviruses. Identical residues to Machupo virus have been replaced with 
dots. Machupo virus GP1 sites that make contact with TfR1 (Abraham et al., 2010) are 
indicated with red asterisks.  They fall in loop 7, loop 10, and in two upstream regions 
which are not shown. Loop 10 is longer in length in Machupo virus compared to all other 
viruses. The numbering scheme is based on the Machupo virus protein. Note that the 
alignment differs somewhat from a similar alignment shown in (Abraham et al., 2010). 
The differences in these alignments concern the exact placement of insertions and 
deletions, but are within the range to be expected from different alignment approaches. 
This alignment was generated using MAFFT (Katoh et al., 2002), (Katoh et al., 2005).  
C, D. Canine D17 cells were transduced to stably express the wild type and chimeric 
TfR1s with C-terminal FLAG tags. Cells were infected with increasing volumes of GFP-
encoding retrovirus pseudotyped with C) Sabia, or D) Chapare virus glycoprotein (GP). 
Cells were monitored for GFP expression to determine the percentage of infected cells.  
Error bars indicate standard deviation of three technical replicates. Experiments were 
performed 2 times with similar results seen in both experiments, graph represents data 
from one experiment. A t-test was performed to determine if differences between mean 
values were statistically significant, * <1e-5, ** <1e-10. Cell surface expression of TfR1 
was monitored with a FLAG antibody via flow cytometry (inset) concurrently with 












Sabia virus GP1 is four amino acids longer upstream of loop 10, compared to 
other viruses such as Junin, Chapare, and Guanarito (Figure 2.3B). To confirm that the 
unique pattern of entry through these modified rat TfR1 receptors was not a result of this 
elongated GP1 motif, we tested entry of Chapare virus, another zoonotic virus closely 
related to Sabia virus (Figure 2.1) but lacking the 4 amino acid insertion (Figure 2.3B). 
We saw the same result, where this virus entered cells equally through the rat-short and 
rat-long TfR1 (Figure 2.3D). Further, we saw additional virus-specific effects in that, for 
Sabia virus, rat-short and rat-long TfR1 permitted less viral entry than the C. callosus 
TfR1, while in the case of Chapare, they permitted more. This result demonstrates the 
complexities of predicting host-virus compatibility in nature, where both host and virus 
genetic variation have functional consequences. 
  
Previously, a human SNP in the arenavirus-binding region of TfR1, L212V 
(Figure 2.4A), was found to reduce entry by Machupo virus (Figure 2.4B) (Demogines et 
al., 2013). It was not previously investigated whether this phenotype was due to reduced 
interaction affinity. We purified the SNP variant TfR1 L212V protein (Figure 2.2E) and 
again performed an ELISA to measure interaction with Machupo GP1. We found that 
TfR1 L212 bound much more tightly to Machupo virus GP1 than did TfR1 L212V 
(Figure 2.4C), in concordance with the entry phenotypes observed. The EC50 values of 
L212 and L212V TfR1 binding to GP1 were 2.1 + 0.37 nM and >1µM, respectively. 




appears to result in a modest amount of virus entry (Figure 2.4B). This could be because 
the strength of the interaction is compounded through avidity effects, or because the 
ELISA results underestimate binding due to a high off-rate that may not be as relevant to 
entry. In contrast, TfR1 binding to iron-loaded human transferrin was not affected by this 
amino acid change (Figure 2.4D). 
 
We next tested two other zoonotic New World arenaviruses for entry through the 
L212 or L212V allelic variants of human TfR1. We tested one arenavirus that is closely 
related to Machupo (Junin virus) and one that is distantly related (Sabia virus) (Figure 
2.1). In contrast to what we found for Machupo virus, TfR1 L212V supported higher 
levels of entry than the more common TfR1 L212 allelic form, and this was true for both 
the Junin virus (Figure 2.4E) and the Sabia virus (Figure 2.4F). In sum, successful 
pairings between viruses and TfR1 depended on sequence determinants in both the host 
and virus. For this reason, we next investigated the prospects for quickly screening the 














Figure 2.4. Human TfR1 L212V SNP has an opposite effect on the entry of related 
arenaviruses  
 
A. The L212 residue in TfR1 contacts loop 10 in the Machupo virus GP1 (PDB Code: 
3KAS)(Abraham et al., 2010).  B. Canine D17 cells were transduced to stably express the 
human TfR1 with either L212 or bearing the human SNP mutation, L212V, both with a 
C-terminal FLAG tag. Cells were infected with increasing volumes of a GFP-encoding 
retrovirus psuedotyped with Machupo virus glycoprotein. Cells were monitored for GFP 
expression to determine the percentage of infected cells.  Error bars indicate standard 
deviation of three technical replicates. Experiment was performed 2 times with similar 
results seen in both experiments, graph represents data from one experiment. A t-test was 
performed to determine if differences between mean values were statistically significant, 
* <1e-3. Cell surface expression of TfR1 was monitored with a FLAG antibody via flow 
cytometry (panel on right) concurrently with measurement of GFP signal. Expression is 
given as mean fluorescent intensity (MFI).  C.  ELISA comparing the relative binding 
affinities of the purified human L212 and L212V TfR1 to Machupo virus GP1.  Purified 
TfR1 was bound to wells.  GP1 was then incubated at decreasing concentrations to 
determine the relative binding affinities. Error bars indicate standard deviation of three 
technical replicates. Experiment was performed 2 times with similar results seen in both 
experiments, graph represents data from one experiment. Curves were fit using 4 
parameter non-linear regression. D. ELISA comparing the relative binding affinities of 
the purified human L212 and L212V TfR1 to iron loaded human transferrin. For the 
ELISA, purified TfR1 was bound to wells.  Iron-loaded TfR1 was incubated at 
decreasing concentrations to determine the relative binding affinities. Error bars indicate 
standard deviation of three technical replicates. Experiment was performed 2 times with 
similar results seen in both experiments, graph represents data from one experiment. 
Curves were fit using 4 parameter non-linear regression. E, F. The experiment is the 
same as in panel B. In this case, cells were infected over increasing volumes with a GFP-










Structure-Based Prediction of Host-Virus Compatibility 
 
 It would be useful to be able to computationally predict whether a virus of one 
species is compatible with the receptor encoded by another species. Towards this goal, 
we developed a computational pipeline for assessing the effect of species-specific 
mutations in TfR1 on GP1 binding (Figure 2.5A). In brief, we used the Machupo virus 
GP1–human TfR1 co-crystal structure (PDB Code: 3KAS) and MODELLER (Eswar et 
al., 2006), (Webb and Sali, 2014) to build homology models of Machupo GP1–TfR1 
complexes, with species-specific substitutions made in TfR1. The substitutions in TfR1 
that we modeled were the same species variants, alleles, and chimeric constructs 
described in the experimental sections above. We then fine-tuned these models through 
re-docking with RosettaDock (Chaudhury et al., 2011). The docking procedure yields 
characteristic “binding funnels” with the best (i.e., most negative) scores falling into a 
narrow range of root-mean-square deviations (RMSDs) relative to the starting 
conformation (i.e., the models from MODELLER) (Figure 2.5A).  We used the 
distribution of the top-10 best interface scores as our final measure of the predicted 
binding strength between the Machupo GP1 and the given TfR1. 
 
 We tested this method on the eight TfR1 variants discussed in this study: human, 
human L212V, mouse, the mouse-human chimera, rat, rat-short, rat-long, and C. callosus 




findings. TfR1s that functioned as partial or full receptors for Machupo virus in entry 
assays (colored yellow and green in Figure 2.5C) had systematically lower (i.e., better) 
interface scores than TfR1s that did not function as receptors for Machupo virus (colored 
red in Figure 2.5C). The model accurately predicted the better binding of Machupo GP1 
to wild-type human TfR1 compared to the TfR1 L212V variant. Recapitulating the 
experimental work done previously (Radoshitzky et al., 2008), it also predicted the 
successively greater binding strength of Machupo virus GP1 to mouse TfR1, then mouse-
human chimeric TfR1, followed by human TfR1. The model predicted that rat-short TfR1 
bound to Machupo virus with affinity that is greater than rat TfR1 but less than C. 
callosus TfR1. One prediction was not completely in line with our experimental 
observations. Rat-long TfR1 was accurately predicted to bind Machupo virus with an 
affinity greater than rat TfR1, but was not predicted to bind differently than rat-short 
TfR1 as was our observation. Thus, we found that we could reasonably model Machupo 
GP1 binding to TfR1 in a way that is predictive of whether the virus would be able to 
enter cells through the TfR1 of different species. We attempted to apply this modeling 
approach to the other arenavirus strains that we had used in our entry assays, but we 
found that we were unable to obtain satisfactory homology models and docks due to low 
template-target sequence identity. Although our approach has this and other limitations, 
discussed further below, it provides a way to quantify a critical determinant of the cross-











Figure 2.5. Computational modeling of Machupo virus GP1 binding to different TfR1 
variants.  
 
A. The computational pipeline consisted of homology modeling of variant TfR1 to the 
template co-crystal of the TfR1 – GP1 interaction, followed by structural refinement and 
re-docking. The re-docking procedure yields a characteristic “binding funnel” of low-
energy conformations at around 8Å root-mean-square deviation (RMSD) relative to the 
starting position before docking. We use the top 10 best (i.e., lowest) scores to compare 
predicted binding strength, as shown in cartoon in the final panel. B. Binding funnels for 
the eight models we analyzed. Each dot shows the Rosetta interface score and RMSD 
from the un-docked configuration for one of the 10,000 docked models we generated. C. 
Comparison of the top-10 best scores across all models considered for each variant TfR1. 
Each boxplot shows the distribution of the interface scores for the 10 best docked 
conformations for each model. The red, yellow, and green color-coding refers to the 
ability of each TfR1 to act as a receptor for Machupo virus, based on experimental results 
presented herein, or elsewhere for mouse TfR1 (Radoshitzky et al., 2008), (Demogines et 
al., 2013), and the mouse-human TfR1 (Radoshitzky et al., 2008).  (One note should be 
made regarding the color coding of mouse-human TfR1 as green. In the previously 
published work, the mouse-human TfR1 became fully functional for virus entry only 
when another mutation, K348N, was also included (Radoshitzky et al., 2008). On the 
other hand, K348N alone did not change the functionality of TfR1 for entry (Radoshitzky 








Entry receptors are species-specific in their interactions with many viruses, so 
their characterization in wildlife populations is imperative. Understanding the role of 
receptors in defining the host range of viruses is important for understanding virus 
spillover to new animal hosts and to humans, and to the development of model organisms 
in which to study viral pathogenesis in the lab (Meyerson et al., 2015), (Sawyer and Elde, 
2012). Here we propose a combination of computational and experimental approaches to 
map out the possible host space of a particular virus. Our approach is general and could 
be applied towards studying the potential spillover risk of many viruses, and their 
interactions with host factors beyond TfR1. 
This work has uncovered potential evolutionary trade-offs in the TfR1-arenavirus 
system. We have shown that a human SNP in TfR1 offers resistance to one virus while 
making the receptor more vulnerable to other viruses. While this SNP is found in Asia, 
and not in regions of the world where New World arenaviruses are found (Demogines et 
al., 2013), one could imagine a situation where selection starts operating on a SNP due to 
a local infection by a virus to which it offers protection, causing its rise in frequency. 
This mechanism, however, would create a population that is potentially more vulnerable 
to the zoonotic transmission of other viruses. A similar trade-off was evident in the 
mutational analysis of rat TfR1. Here we saw that, for Sabia virus, rat-short and rat-long 




they were better. With receptors, then, a complex fitness landscape can arise where 
resistance to one pathogen may come at the expense of susceptibility to others.  
 
In the experiments that were performed, a small number of amino acid 
substitutions in rat TfR1 (rat-short and rat-long) transformed it into a functional receptor 
for several arenaviruses. This would suggest that SNPs in this region of TfR1, potentially 
already circulating in rat populations, could lead to individuals that are more susceptible 
to some arenaviruses and hence might ultimately become carriers of these viruses. This 
could provide a conduit for host range expansion into a species that is found globally. 
 
Signatures of positive selection can be a valuable guide to mapping species-
specific determinants of virus-receptor compatibility. All that is required to test for 
positive selection is a sequence alignment of the receptor gene, specifically from species 
which have served as the long-term viral reservoir.  As we have now illustrated with 
rodent arenaviruses and retroviruses (Demogines et al., 2013), canine parvoviruses 
(Kaelber et al., 2012), bat SARS-like coronaviruses (Demogines et al., 2012), and 
primate lentiviruses (Meyerson et al., 2014), the use of evolutionary analyses to finely 
map the viral interaction surfaces on entry receptors seems to be accurate in many 
contexts, and can guide the rapid characterization of the host protein receptors that 
govern species tropism of many emerging viruses. Similar phenomena have also been 




(C. Martin et al., 2013). Reciprocally, positively selected sites in genes encoding viral 
glycoproteins can identify the host-receptor binding site (Demogines et al., 2013), (Meyer 
and Wilke, 2015).  
 
Indels have accumulated in a region of arenavirus GP1 (loop 10) that contacts 
TfR1. These changes, combined with positive selection for non-synonymous mutations in 
portions of the GP1 that contact TfR1 (Demogines et al., 2013), have resulted in GP1 
proteins of arenaviruses being highly divergent. As a consequence, the application of 
positive selection analysis, phylogenetic studies, and genetic mapping studies to this 
system becomes difficult, as all of these methods require quality alignments of viral 
sequences.  To help solve this problem, more extensive surveillance of viruses could 
provide intermediate sequences that resolve the location of indels in viral alignments.  
Also, multiple co-crystal structures in this system, for instance the GP1 of several 
different arenaviruses in complex with the TfR1 of their relative host species, could help 
elucidate how well or poorly the binding architecture has been preserved. 
 
The structural docking method described here can be used to evaluate the effects 
of mutations at the receptor–virus interface, similar to what was also done in a recent 
study with Middle East respiratory syndrome coronavirus (MERS-CoV) and its receptor 
DPP4 (van Doremalen et al., 2014). Relative to molecular dynamics methods used 




system (Meyer et al., 2014), the docking method described here is much less 
computationally expensive. While we showed that our structural docking method works 
well in several contexts in this study, there are limitations.  Most obvious is the fact that a 
co-crystal structure of the interacting proteins in complex is required. While co-crystals 
are not yet available for many host-virus systems, the number of such structures is 
quickly growing. It is possible to thread related proteins onto these structures, but we 
have found that this procedure was more accurate for the host protein, TfR1, than for the 
viral protein, GP1. Rodent and human TfR1s display only moderate divergence and thus 
can be reliably homology-modeled: all rodent TfR1s analyzed share greater than 70% 
identity with human TfR1. By contrast, GP1 sequences from different arenaviruses are 
too divergent to be modeled via homology, due to both the length differences found 
specifically in the loop 10 binding region and their low amino-acid conservation 
(Machupo GP1 residues 87-242 share only 25% to 46% identity with the corresponding 
GP1 residues of Junin, Guanarito, and Sabia) (Abraham et al., 2010). When we tried to 
model the GP1 of other arenaviruses, they would generally not dock reliably to any TfR1 
variant considered (not shown). 
 
There are several extended applications that can be envisioned for structural 
docking. First, the TfR1 of rodents with overlapping geographic ranges to C. callosus 
could be tested to see if there are other rodent species to which spillover of Machupo 




increased risk for humans in those areas. Second, mutations in viral surface glycoproteins 
could be tested in this model to see which would make the virus better at binding versions 
of the receptor encoded by new hosts, including humans or new rodent species.  These 
would constitute virus mutations of interest to wildlife surveillance projects. Finally, the 
results with the L212V TfR1 SNP suggest that this model can be used to quickly predict 
the functional effects of human or rodent SNPs.  Co-crystal structures describing relevant 
host-virus protein-protein interactions are the main limitation in this approach. This 
approach is in its infancy and will be refined by applying it to various problems and 
learning from its strengths and weaknesses. Investment in the generation of more co-
crystal structures demonstrating interactions between host- virus interaction partners 
would be fruitful considering the success of the docking approach applied here for 
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Chapter 3 Discovery of a Panel of Anti-Ebola Virus Antibodies by 




Ebolaviruses are negative-sense RNA filamentous viruses that cause very high 
morbidity and mortality (Bowen et al., 1977). Host cell entry is mediated first by the 
attachment of the heavily glycosylated glycoprotein (GP) on the viral envelope to the 
host cell encoded T-cell immunoglobulin and mucin domain 1 (TIM-1) (Kondratowicz et 
al., 2011). Following cathepsin cleavage in the lysosome, GP mediates cellular entry by 
binding the host cell encoded Niemann-Pick C1 (NPC1) (Carette et al., 2011). Five 
antigenically distinct ebolaviruses exhibiting 35-45% genome sequence divergence have 
been discovered (Towner et al., 2008): Ebola virus (abbreviated as EBOV, formerly 
designated as Zaire ebolavirus); Sudan virus (SUDV); Bundibugyo virus (BDBV); 
Reston virus (RESTV, for which no zoonotic infections have been reported to date) (M. 
E. G. Miranda and N. L. J. Miranda, 2011); and Taï Forest virus (TAFV, one incident of 
human infection) (Le Guenno et al., 1995). The recent EBOV outbreak in West Africa, 
                                                
2 This work was adapted with permission from Wang B, Kluwe CA, Lungu OI, DeKosky BJ, Kerr SA, 
Johnson EL, Jung J, Rezigh AB, Carroll SM, Reyes AN, Bentz JR, Villanueva I, Altmam AL, Davey RA, 
Ellington AD & Georgiou G. Facile Discovery of a Diverse Panel of Anti-Ebola Virus Antibodies by 
Immune Repertoire Mining. Scientific Reports. Nature Publishing Group; 2015;5: 13926. 
doi:10.1038/srep13926. Scott designed and executed the experiments presented here with cloning and 
ELISA assistance from Jiwon Jung and Bo Wang.  Scott processed and analyzed the data under the 




centered in Guinea, Sierra Leone, and Liberia with isolated outbreaks in Nigeria and 
Mali, was the largest ever with a mortality rate estimated at 70% of recorded definitive 
clinical outcomes (http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/index.html)  
(Team, 2014). Phylogenetic comparison of isolates from the recent outbreak (Baize et al., 
2014) with 20 Ebolavirus genomes from earlier outbreaks suggested that the 2014 West 
African virus likely spread from central Africa within the past decade, having diverged 
from a common ancestor around 2004 (Gire et al., 2014). The five Ebolavirus species 
have varying rates of molecular evolution, with the highest of 8.21x10-4 nucleotide 
substitutions/site/year for Reston virus (Carroll et al., 2013). The ongoing evolution of 
Ebolaviruses poses significant challenges to the development of immunodiagnostics. 
Specifically, there is a critical need for the discovery of panels of monoclonal antibodies 
with distinct affinities and specificities for different Ebolaviruses. Of particular 
importance is the Reston Virus, to date there are no reported antibodies that can bind the 
glycoprotein of the Reston Virus 
Antibodies to EBOV and SUDV have been produced from hybridomas (Dias et 
al., 2011), (Qaiu et al., 2011);  by in vitro screening of synthetic scFv libraries 
(Koellhoffer et al., 2012), (Chen et al., 2014), and from human immune antibody libraries 
constructed from infected individuals (Maruyama et al., 1999). However additional 
monoclonal antibodies to Ebolaviruses are urgently needed both for diagnostic purposes 
and as therapeutics (Parren et al., 2002), (Qiu et al., 2014). Specifically, the generation of 




GP, which is heavily glycosylated in a host cell-specific manner (Feldmann et al., 1994), 
(Lin et al., 2003) and subjected to proteolytic cleavage during entry (Hood et al., 2010), 
as well as by the sequence diversity of the Ebolaviruses. Finally, characterization of 
useful antibodies to Ebolaviruses is limited by the safety concerns associated with 
handling the live virus. 
Antibody discovery has relied either on the immortalization (Köhler and Milstein, 
1975) or cloning of antibodies isolated from individual B cells obtained from an antigen-
challenged host (Reddy et al., 2010), (Saggy et al., 2012), (Lane and Koprowski, 
1982), (Ghosh and Campbell, 1986), (Wu et al., 2010), (Corti et al., 2011) or, 
alternatively, on the in vitro isolation from combinatorial libraries using a variety of 
screening techniques (Bradbury et al., 2011). The current collection of antibody 
technologies is predicated on the isolation of clones that display high antigen binding. 
However, animal immunization induces the stimulation and expansion of a highly diverse 
population of B cells encoding an antibody repertoire with a wide range of antibody 
affinities (Reddy et al., 2010), (Saggy et al., 2012). Antibodies with low affinity 
nonetheless may exhibit other highly desirable properties, including broad cross-
reactivity or heteroclitic specificity, i.e. stronger binding reaction to a different antigen 
other than the one used for immunization (Lane and Koprowski, 1982), (Ghosh and 
Campbell, 1986), (Van Regenmortel, 2014). Unfortunately, there is no straightforward 
way to identify such interesting antibodies. For example, while the isolation of antibodies 




rapidly evolving pathogens such as HIV-1 or flu has been accomplished by B cell 
cloning, the process typically requires the screening of many thousands of B cells and 
therefore is very laborious and expensive (Wu et al., 2010), (Corti et al., 2011), (Walker 
et al., 2011), (Walker et al., 2009). 
In order to satisfy the need for a wider variety of antibodies to Ebolaviruses, we 
developed a novel approach to comprehensively mine the full suite of antibody diversity, 
shaped by in vivo selective mechanisms and generated within the boundary of reactive 
secondary lymphoid tissues in immunized animals. We reasoned that antibodies encoded 
by antigen-stimulated B cells that had undergone the greatest degree of expansion within 
the confinement of a secondary lymphoid organ are most likely to display desirable 
antigen recognition properties including heteroclite recognition of diverse Ebolaviruses. 
Briefly, mice were first immunized in the footpad with Ebola virus-like particles (VLPs).  
Footpad immunization triggers a strong and highly-focused immune reaction in the PLN, 
especially for particles <40 nm such as VLPs (Reddy et al., 2006). Antigen experienced, 
CD138+ B cells (plasmablasts) from the PLN were isolated and the natively paired VH:VL 
repertoire encoded by these cells was determined by NextGen sequencing (DeKosky et 
al., 2013). Antibodies corresponding to the highest frequency VH:VL pairs, and thus likely 
arising from the most clonally expanded and highly-transcribing CD138+ B cells within 
the PLN, were expressed recombinantly and their binding properties were characterized. 




antibodies. (RESTV, Reston, 1996, NCBI Accession number AB050936), an Ebolavirus 
for which no anti-GP monoclonal antibodies are available. 
 
RESULTS  
Immunization of the PLN yields antigen-specific antibodies  
 
Fig. 3.1 summarizes our approach for mining the antibody repertoire encoded by 
the most highly expanded, antigen-experienced B cells following antigen stimulation. 
Footpad immunization leads to a strong inflammatory response in the draining popliteal 
lymph node (Fig. 3.1a). Unlike lymph nodes that drain sites of frequent extracorporeal 
interaction (e.g. the oral cavity or lungs), the germinal centers of the popliteal lymph 
node are normally relatively unstimulated (Kamala, 2007). Footpad immunization results 
in a marked increase in cellularity in the ipsilateral popliteal lymph node relative to the 
unstimulated contralateral lymph node (Gleichmann, 1981), (Ravel and Descotes, 2005), 






Figure 3.1: Isolation of antibodies by mining the paired VH:VL repertoire of  draining 
popliteal lymph node (PLN) antibody-secreting B cells.  
(a) Footpad immunization leads to a marked increase in cellularity within the ipsilateral 
popliteal lymph node (PLN) relative to the contralateral lymph node (red and black 
arrows respectively). (b) PLN CD138+ cells isolated by magnetic sorting are deposited 
into 125 pL wells on PDMS slides that also contain poly(dT) beads.  Cells are lysed in 
situ and mRNA is captured on the poly(dT) beads (DeKosky et al., 2013). (c) The 
poly(dT) beads are emulsified and VH:VL amplicons are generated following reverse 
transcription and overlap extension PCR. (d) VH:VL amplicons are sequenced using 
Illumina 2x250 MiSeq and the highest frequency VH:VL pairs are identified via 
bioinformatics analysis. (e) Highest frequency VH (orange) and VL (green) genes are 
synthesized and cloned into IgH and IgL expression vectors containing human IgG1 
(blue) and human kappa (yellow) constant regions, respectively. (f) Following co-






Ebola VLPs were produced by co-transfection of HEK293FT cells with plasmids 
encoding the three major virus structural proteins: nucleoprotein (NP), VP40 and GP of 
the RESTV strain and were purified by sucrose density centrifugation. Electron 
microscopy and gel staining confirmed that the other ebola VLPs created with the same 
process displayed a morphology and consistency characteristic of EBOV virions (Fig. 
3.2.). Three mice were immunized with Ebola VLPs in emulsified adjuvant in the left 
hind footpad, followed by boost immunization in the lateral hock to minimize pain and 
discomfort. After the second boost, a strong anti-VLP titer was observed in all three mice 
and a weaker anti-GP was observed indicating that a portion of the immune response was 
against other, non-GP elements of the VLP (Figure 3.3). A final boost was administered 


















Figure 3.2: VLP production and characterization.  
 
 (a) Transmission electron microscopy images of EBOV VLPs. VLPs were purified by 
sucrose gradient and imaged using transmission electron microscopy. Particles of 
heterogeneous size were visible and examples are shown. (b,c) Total protein (left panel) 
and immunoblot (right panel) analysis of Ebola (b) and Bundibugyo (c) virus VLPs. 
VLPs were generated by transfecting plasmids encoding NP, VP40 and GP into 293FT 
cells. VLPs from culture supernatants were pelleted through sucrose and then applied to a 
sucrose gradient (S). Fractions were then collected from top (1-4) and material pelleting 
also collected (5). Gels were either stained with krypton total protein stain (left panels) or 
with VP40 (green) and GP (red) specific antibodies (right panels). Bundibugyo VLP 


















CD45R-CD19-CD138+ antibody secreting B cells were enriched by magnetic 
sorting and the paired VH:VL repertoire from single cells was determined following 
sequestration of the cells into 125 pL wells on PDMS slides (DeKosky et al., 2013) (Fig. 
3.1b). Approximately 1x105 CD45R-CD19-CD138+ plasmablasts were isolated by 
magnetic sorting, of which 2.5-3.5x104 cells were processed to create natively paired 
VH:VL amplicons. Linked VH:VL amplicons of approximately 850 bp were generated and 
then sequenced using Illumina MiSeq technology (Fig. 3.1c). High quality reads were 
clustered based on the CDRH3:CDRL3 sequences (Fig. 3.1d).   
 
Figure 3.3 – Bleed/Injection Schedule and Bleed 3 Titers 
Mice were injected every two weeks with Reston-Ebola VLPs. Serum was collected prior 
to injection and ~one week after the 2nd, 3rd and 4th injection.  Mice were sacked 6 days 
after the final injection.  Titers were determined using serum from the bleed following the 
3rd VLP injection.  Titers were measure against VLPs that were used to immunize and 




THE PLN PLASMABLAST IGG REPERTOIRE ELICITED BY IMMUNIZATION WITH EBOV  
 
641, 572, and 546 unique VH:VL pairs (represented by ³2 sequence reads per pair 
each), comprising the PLN plasmablast repertoires were identified in mouse 1 (M1), 
mouse 2 (M2) and mouse 3 (M3),  respectively. The repertoires from both Ebola VLPs 
immunized mice investigated were skewed, with the top ten most abundant VH:VL pairs 
representing 52%, 33% and 31% of the total sequence counts in each mouse, respectively 


















Mouse 1 - 641 Clonotypes    Rank Sequence Reads % of Total Reads CDRH3 CDRL3 
RM1.1 27714 17% CARGAITTGFAYW CQNDHSYPLTF 
RM1.2 11534 7% CARQGYRYGLYAMDYW CQQWSSYPTF 
RM1.3 10054 6% CVGGDYW CQQWSSYPLTF 
RM1.4 7433 5% CTRAIGRAMDYW CQQSNEDPYTF 
RM1.5 6978 4% CTRGDDGAWFATW CQQWSSNPFTF 
RM1.6 5625 3% CARSKFITTSMDYW CHQHYNTPRTF 
RM1.7 5475 3% CTRGWDGIAYW CQQDYSSPRTF 
RM1.8 4428 3% CARQGVLTIDYW CHQWTSYPWTF 
RM1.9 4220 3% CARGVWSPYFDYW CSQSTHVPYTF 
RM1.10 3527 2% CARHYYGSRDYFDYW CQQHYSTPWTF 
     Mouse 2 - 572 Clonotypes    Rank Sequence Reads % of Total Reads CDRH3 CDRL3 
RM2.1 2273 7% CARYRYAMDYW CHQWSSYRTF 
RM2.2 1477 4% CARPYYGMDYW CQQSNEDPWTF 
RM2.3 1316 4% CARRDGYYWYFDVW CQQGNTLPWTF 
RM2.4 972 3% CARWGWVGAMDYW CQQSNSWPLTF 
RM2.5 934 3% CARGGYGSPFAYW CFQGSHVPFTF 
RM2.6 855 3% CARSYYDYDEGLGYYAMDYW CHQYHRSPYTF 
RM2.7 832 3% CARQGRSYFYALDYW CAQNLELPYTF 
RM2.8 814 2% CARQTNSFDYW CQQWSSNPYTF 
RM2.9 682 2% CARDGEVRRRYYAMDYW CQHSWEIPLTF 
RM2.10 663 2% CARQPFDYW CFQGSHVPYMF 
     Mouse 3 - 546 Clonotypes    Rank Sequence Reads % of Total Reads CDRH3 CDRL3 
RM3.1 1897 5% CARGGDGSYVRAMDYW CHQRSSFPLTF 
RM3.2 1518 4% CARSGGTNW CWQGTHFPLTF 
RM3.3 1380 4% CARHSPSYGNFAWFAYW CQQWSNPPWTF 
RM3.4 1093 3% CVLEAFDYW CQQRSSYPFTF 
RM3.5 1031 3% CASQIYYGYDEGFDYW CHQRSSYHTF 
RM3.6 1003 3% CARRRNYFAMDYW CQQGNTLPWTF 
RM3.7 985 3% CARGIGGGFAYW CQQNNEGPYTF 
RM3.8 902 2% CARDWDVAYW CQQRSSYPPTF 
RM3.9 873 2% CARETGRNYGYSYVMDYW CQQRTSYPLTF 
RM3.10 727 2% CASDYDGAMDYW CHQYHRSPWTF 
Table 3.1: Top ten VH:VL pairs. 
The top ten VH:VL pairs as ranked by total number of sequence reads from sequencing 
run.  The % of the total sequencing reads for each pair was calculated.  The CRDH3 and 





Construction and characterization of anti-EBOV VLP antibodies 
 
The 7 highest frequency VH:VL clonotypes from each mouse were selected for 
characterization. Antibody genes for these 21 most prevalent VH:VL antibody clonotypes 
were synthesized and cloned as mouse V region-human constant domain chimeric 
antibodies, expressed in HEK293 cells, and characterized for antigen binding. We 
identified three antibodies designated RM2.4, RM3.2, and RM3.3 that bound to both 
RESTV VLPs as well as to RESTV recombinant GP (Fig. 3.4).  
   
Figure 3.4: Functional characterization of IgG antibodies isolated via mining of RESTV 
immunized PLN CD138+ B cell repertoire.  
Binding to RESTV GP for select antibodies as determined by ELISA. Curves were fitted 
using 4-parameter non-linear regression. Error bars represent the standard deviation for 








Here we report an approach for generating a panel of distinct monoclonal 
antibodies that bind RESTV GP. We found that in multiple animals immunized with 
RESTV VLPs, the repertoire of CD138+ plasmablasts in the draining PLN contained 
highly expanded, antigen-specific, antibody sequences. We find that these highly 
expanded sequences include antibodies that display affinity to GP. These results 
demonstrate the power of mining the antibody repertoire of highly expanded B cells after 
immunization for discovery of antibodies with interesting properties.    
The ability to isolate distinct antibodies with very different CDR3 sequences per 
animal as well as a much larger number of somatic variants whose sequences are also 
available in the VH:VL sequence database provides a rich source of antibodies for 
practical purposes. Undoubtedly, many PLN B cells encoding antigen-specific antibodies 
are likely to have been subject to more limited expansion and thus are present at a lower 
abundance within the repertoire. However, such medium or low abundance antibody 
sequences within the repertoire are present at comparable levels to those elicited by 
environmental stimuli and thus recognizing unrelated antigens.  Therefore the low 
abundance antigen-specific antibody sequences in the repertoire cannot be identified 
directly without significant additional effort.   
In case of rapidly spreading emerging diseases such as Ebola, rapid and robust 
diagnostics are critical for treatment and disease control. For Ebola in particular, 




available. Highly sensitive antibody based immunodiagnostics are extremely important 
and easy to implement (Towner et al., 2008). However, a dearth of monoclonal 
antibodies for emergent Ebolaviruses limits the ability to use antigen-capture 
technologies for viral identification of early-stage infections. The panel of antibodies 
identified and characterized here should be useful for diagnostic applications that aim to 
identify Reston Ebola. By using multiplex immunoassay platforms such as the Luminex 
MagPlex® technology, it should be possible to multiplex up to 50 different antibodies 
with varying specificities for a broad range of epitopes, thus ensuring wide coverage of 
Ebolaviruses variants. Studies to incorporate the antibodies we have described here onto 
the Luminex MagPlex® diagnostic platform for field applications are on-going. 
METHODS 
VLP Production and Characterization 
 
VLPs were produced by co-transfection of HEK293FT (Invitrogen) cells with 
plasmids encoding the three major virus structural proteins, NP, VP40 and GP. All open 
reading frames for virus structural proteins were obtained from NCBI and were codon 
optimized for mammalian cell expression using Gene Designer (DNA 2.0), synthesized 
(Epoch Life Science) and inserted into either pcDNA3 (for Ebola GP) or pCAGGS (all 
other genes) mammalian expression plasmids. Cells were transfected with each of 5 ug 
NP, 5 ug VP40 and 1 ug GP encoding plasmids by the calcium chloride/BES transfection 




containing 10% (v/v) FBS. After an additional 24 h, the culture supernatant was collected 
and clarified by centrifugation at 3750 rpm for 30 min at 4oC to remove cell debris. The 
supernatants were then overlaid onto a 5 mL 20% (w/v) sucrose cushion in 20 mM NaCl, 
20 mM HEPES, pH 7.4 in an SW28 ultracentrifuge tube (Beckman). The VLPs were then 
pelleted by centrifugation at 28,000 rpm for 2 h at 4oC in an SW28 rotor. To further 
purify VLPs, the pellet was resuspended in PBS and overlaid onto a 20 to 60% sucrose 
step gradient (5% increments) in 20 mM NaCl, 20 mM HEPES, pH 7.4 in a SW55 rotor 
tube (Beckman). The gradient was centrifuged at 38,000 rpm for 2 h at 4oC after which 
an opaque band corresponding to VLPs was visible. Fractions were collected 
corresponding to the band as well as directly above and below it and analyzed by SDS-
PAGE, staining for total protein with Krypton stain (Thermo Scientific) as well as 
immunoblotting. The middle fraction containing the peak of the VLPs was stored at -
80°C until required. For immunoblotting, proteins were transferred to nitrocellulose 
membranes and stained using broadly reactive polyclonal antibodies against GP (gift 
from Dr. Andrew Hayhurst, Texas Biomedical Research Inst.), VP40 (gift from Dr. 
Ricardo Carrion, Texas Biomedical Research Inst.) or NP (IBT Bioservices). A specific 
monoclonal antibody against Zaire Ebolavirus GP was also used (4F3, IBT Bioservices). 
Appropriate secondary antibodies were purchased from LiCor Biosciences. Blots were 
imaged using a LiCor Odyssey SA imager. Electron microscopy of VLPs was performed 
at the University of Texas Health Sciences Center, San Antionio, Department of 




were fixed in glutaraldehyde and osmium tetroxide was used as contrast agent. Images 
were captured on a Philips 208S digital imaging electron transmission microscope. 
Immunizations and Serum Titer Determination 
 
The study was approved by the University of Texas Institutional Animal Care and 
Use Committee (AUP-2013-00015). All animal experiments were carried out in 
accordance with the approved protocol. VLPs in PBS pH 7.4 were emulsified in a 1:1 
ratio with TiterMax Gold adjuvant (Sigma). For footpad immunizations, 20 µL 
(containing a total of 5  g VLPs) antigen/adjuvant mixture was injected into the 
subcutaneous space of three BALB/c mice; for lateral hock injections, up to 50 µL was 
injected into the subcutaneous space just proximal to the lateral aspect of the ankle. Mice 
were immunized at footpad on day 0 for primary immunizations, and in the lateral hock 
on days 21, 35, and 77 for secondary immunizations. At days 10, 28, and 42 mice were 
bled for titration of the antigen-specific response. In order to determine serum antibody 
titer, mice were restrained in a tube restrainer, the tail wiped with isopropyl alcohol, and 
small incisions made with a fresh scalpel blade to nick the tail vein.  20-50 µL blood was 
obtained and allowed to coagulate at room temperature (RT) for 30 min, followed by 
centrifugation at 13,000 g for 15 min to pellet the clot.  The serum was then used for 
ELISA assays. High binding ELISA plates (Corning) were coated overnight (O/N) at 4°C 
with 50 µL of 4 µg/mL Zaire Ebolavirus VLPs in PBS pH 7.4.  Antigen solution was 




solution was then decanted and plates were then incubated with 50 µL of serum diluted 
three-fold from 1:100 to 1:218,700 in 2% milk (w/v) in PBS for 1 h.  Plates were then 
aspirated and washed 3 times with PBS containing 0.05% tween-20 (PBST), then 
incubated with 50 µL of 1:5000 diluted goat anti-mouse HRP secondary antibody 
(Jackson ImmunoResearch) for 1 h.  Plates were washed 3 times with PBST, and 
incubated with 50 µL TMB-Ultra (Thermo Scientific) for 15 min.  The reaction was 
quenched with 50 µL 2 M H2SO4 and absorbance was read at 450 nm on a Tecan M200 
plate reader.  
 
Tissue Collection, Cell Isolation, and Subtype Purification 
 
After determination of significant titer for Ebolavirus VLPs (signal evident above 
background at dilution > 1:10,000), mice were administered a final boost at day 77, and 
lymph nodes were collected 6 days later. For lymph nodes collection, mice were injected 
with 5-10 µL of 2% Evans Blue (Sigma) in PBS into the footpad.  30 min post-injection, 
mice were sacrificed by carbon dioxide asphyxiation followed by cervical dislocation.  
The skin and fur around the leg was removed to reveal the blue-stained popliteal lymph 
node (Fig. 3.1a), located just behind the knee. The lymph node was isolated and and 
stored in PBS pH 7.4 supplemented with 0.1% (w/v) BSA, 2 mM EDTA in a 6-well plate 
(Corning). Lymph node was homogenized by mechanical disruption using two 18G 
needles. The cells were then passed through a 70 μm cell strainer (Corning), with 




Cells were then spun down at 500 g for 10 min in a swinging bucket rotor. The cell 
pellets were then resuspended in 2 mL red blood cell lysis buffer (155 mM NH4Cl, 12 
mM NaHCO3, 0.1 mM EDTA) and incubated at room temperature for 3.5 min.  The lysis 
reaction was quenched by adding 20 mL PBS buffer followed by centrifugation at 500 g 
for 10 min at RT. Cells were washed again with 5 mL PBS buffer and resuspended in a 
final volume of 1 mL buffer. Plasma cells were then isolated using the Miltenyi Plasma 
Cell Isolation kit (Miltenyi Biotec). Briefly, non-plasma cells were depleted by magnetic 
labeling of CD49b and CD45R followed by enrichment of magnetically-labeled CD138+ 
cells.  CD45R is a pan-B cell marker expressed on naïve and activated B lymphocytes, 
but not on antibody-secreting cells. Conversely, CD138 is expressed on pre-B and 
immature B-lymphocytes in the bone marrow, lost upon emigration into secondary 
lymphoid tissues, and re-expressed upon differentiation into plasma cells.   
Single Cell VH:VL Sequencing 
 
Sorted cells were analyzed by single B cell VH:VL sequencing as previously 
described (DeKosky et al., 2013).  Briefly, single cells were isolated into 125 pL wells 
printed in PDMS along with poly(dT) conjugated magnetic beads.  Cell lysis and capture 
of mRNA was performed in situ, and beads were collected and emulsified to serve as 
template for emulsion overlap extension RT-PCR. A follow-up nested PCR resulted in 
850 bp amplicons containing linked genetic information for VH and VL genes.  850 bp 




were amplified separately for full-length VH and VL analysis using the Illumina MiSeq 




Raw MiSeq data was analyzed as previously described (DeKosky et al., 2013).  
Briefly, raw data were filtered for a minimum Phred quality score of 20 over 50% of 
nucleotides to ensure high read quality in the CDR3 regions of heavy and light genes.  
Sequence data were submitted to the IMGT information system for V-D-J germline gene 
mapping.  Sequences were filtered for in-frame V-D-J junctions and VH:VL pairs were 
compiled by exact CDRH3:CDRL3 nucleotide match. CDRH3 junction nucleotide 
sequences were clustered to 96% identity and resulting clusters with >=2 VH:VL reads 
were ranked by MiSeq read counts (DeKosky et al., 2013). Due to read length limitations 
of current next-generation sequencing technology, the complete VH and VL genes were 
also sequenced and analyzed separately.  Full-length VH and VL genes were filtered for a 
minimum Phred quality score of 20 over 50% of nucleotides and were compiled by 
CDRH3 and CDRL3 exact nucleotide match.  Consensus sequences of VH and VL genes 
(i.e. from all reads passing quality filters and that contained exact matches to the 
CDRH3:CDRL3 pair of interest) were used for antibody gene synthesis, expression, and 





IgG Synthesis, Expression, and Purification 
 
Consensus VH and VL genes were designed and purchased as gBlocks (Integrated 
DNA Technologies) and cloned into the pcDNA3.4 vector (Invitrogen) containing 
Oryctolagus cuniculus IgG leader peptide as fusions to human IgG1 and kappa constant 
regions, respectively. Sequences of both the heavy and the light chain for each antibody 
variant were confirmed by Sanger sequencing. Plasmids for each antibody variant were 
transfected into Expi293 cells (Invitrogen) at a 1:3 heavy:light ratio.  After incubating at 
37°C with 8% CO2 at 125 rpm for 6 days, the supernatant containing secreted antibodies 
was collected by centrifugation at 500 g for 15 min at 25°C. Supernatant was passed over 
a column of 0.5 mL Protein A agarose resin (Thermo Scientific) three times to ensure 
efficient binding. After washing with 20 column volumes of PBS, antibodies were eluted 
with 3 mL 100 mM citric acid pH 3.0 and immediately neutralized with 500 µL 1M Tris 
pH 8.0. Antibodies were buffer exchanged into PBS, pH 7.4 utilizing Amicon Ultra-30 




Costar 96-well ELISA plates (Corning) were coated with 50 µL of 4 µg/mL 
recombinant Ebola Glycoprotein (a gift from Dr. Erica O. Saphire, The Scripps Research 




they were decanted and blocked with 2% milk in PBS for 2 h at RT.  After blocking, 1:5 
serially diluted antibodies were applied to the plates for 1h, after which 1:5000 diluted 
donkey anti-human IgG HRP-conjuated secondary antibodies were applied (Jackson 
ImmunoResearch) for 1 h.  For detection, 50 µL TMB-Ultra substrate was applied for 15 
min before quenching with 50 µL 2 M H2SO4.  Absorbance was measured at 450 nm 
using a Tecan M200 plate reader. Data were analyzed and fitted for EC50 using a 4-
parameter logistic nonlinear regression model in the Prism software. The 4-parameter 
equation used was: Y=Max + ((Min-Max)/(1+(X/EC50)^HillSlope)).  To ensure 
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Vaccine development is an empirical process, governed by response rates, 
efficacy studies, side effects, the duration of protection, and data gleaned experimentally 
from large, longitudinal clinical studies. However, the current paradigm provides limited 
insights into the molecular mechanism(s) governing protective immunity and is 
inadequate for responding to newly emerging or rapidly evolving pathogens. A major 
goal in vaccinology is to develop molecular metrics of vaccine responsiveness and 
efficacy. This in turn requires precise knowledge of the identity, functionality and 
persistence of the antigen-specific circulating antibodies and B-cells induced by 
vaccination.  
Human Noroviruses (HuNoVs) cause ~85-96% of acute non-bacterial 
gastroenteritis, worldwide. Outbreaks occur in communities, family homes, recreational 
facilities, elderly care facilites, day care centers, schools, cruise ships, hospitals and in 
the military (Farkas et al., 2002), (Glass et al., 2000), (Ho et al., 1989), (Koopmans et al., 
2000), (Koopmans, 2008). HuNoVs are transmitted via ingestion of fecally contaminated 
food and water, exposure to contaminated fomites, vomitus and direct person-to-person 
contact. It has also been recently reported that airborne transmission of the virus may be 




hospitalizations, and 700+ fatal cases per year in the US (Mead et al., 1999). About 13% 
of infections result in post-infectious irritable bowel syndrome (Zanini et al., 2012). 
Worldwide, HuNoV infections cause ~200,000 deaths/yr, mostly in infants (Patel et al., 
2009), (Patel et al., 2008) and are an important cause of severe gastroenteritis in the 
elderly (van Asten et al., 2011). HuNoV infections also cause about ~30-50% of 
travelers’ diarrhea, persist for months in immunosuppressed people, and are Category B 
biodefense pathogens.  
The HuNoV ~7.6 Kb single-stranded, plus-sensed RNA genome encodes 3 open 
reading frames (ORF): a 1738 amino acid (AA) replicase (ORF1), a major capsid protein 
of ~530 AA (ORF2: VP1), and a 212 AA minor capsid protein (ORF3: VP2) (Clarke et 
al., 2015), (Jiang et al., 1993).  The Norovirus phylogeny is subdivided into five 
genogroups (GI-GV), the HuNoV GI and GII strains are ~50% different at the amino acid 
level (Zheng et al., 2006).  The GI and GII strains are the only two genogroups that infect 
humans and they cause ~15% and ~85% of the recent outbreaks, respectively (Zheng et 
al., 2010). GI and GII are further subdivided into ~8 and ~19 genotypes, respectively, that 
differ at the amino acid level by at least ~30% in VP1(Donaldson et al., 2010), (Green et 
al., 2000). Highly epidemic GII.4 strains have caused six pandemics since 1997(Desai et 
al., 2012) and that genotype alone accounts for over 70% of infections (Vega et al., 
2014).  
Norovirus infection requires viral interactions with histoblood group antigens 




cells (Donaldson et al., 2010) or bacterial cells that are hypothesized be shuttling the 
virus into cells (Jones et al., 2014), (Karst and Wobus, 2015).  Infection is specifically 
mediated by interactions between the viral VP1 surface epitope and the host HBGAs.  
Antibodies that bind VP1 and block HBGA interactions are associated with protective 
immune responses in mice, swine, chimpanzees and humans (Bok et al., 2011), (Chachu 
et al., 2008b), (Chachu et al., 2008a).  Therefore a goal in HuNov vaccine development is 
to construct a vaccine that successfully induces the lasting production of antibodies that 
bind VP1 and prevent interactions between the virus and it’s congnate HBGA.  
  A major goal in vaccinology is to develop molecular metrics of vaccine 
responsiveness and efficacy. This in turn requires precise knowledge of the identity, 
functionality, and persistence of the antigen-specific circulating antibodies and B-cells 
induced by vaccine. Information on the V gene repertoire encoded by antigen-specific B-
cells is also necessary.  Of particular importance is the complementary determining 
region of the antibody heavy chain (CDRH3).  The CDRH3 lies at the center of the 
antigen binding site, is the most divergent in terms of sequence, and is usually the 
primary determinant of antibody specificity. Recent advances in high throughput DNA 
sequencing have enabled the in-depth determination of the V gene repertoire of B cell 
subsets in humans and animals (Ippolito et al., 2012), (Reddy et al., 2010), (Wang et al., 
2015), (DeKosky et al., 2013) (McDaniel et al., 2016). We and others have developed a 
number of bioinformatics tools for the analysis of the V gene repertoire including 




the hypervariable complementarity-determining region 3 (CDR3) length in the BCR, and 
aa usage, etc.  
Recently, a biotech company Ligocyte (acquired by Takada), conducted a 
prime/boost (Day 0, Day 28) dose escalation study in human volunteers to test a 
norovirus candidate vaccine (Treanor et al., 2014).  Here we mine both the B-cell 
antibody sequence repertoire and the antibodies in serum from a trial volunteer to 
elucidate the composition of antigen-specific antibodies to the norovirus candidate 
vaccine. 
Using serum and cell samples from a study donor we sought to identify the 
antigen specific antibodies elicited following vaccination. The goal was to determine the 
repertoire and relative level of circulating antibodies specific to HuNoV arose in response 
to the vaccine. The vaccine consisted of equal amounts of two types of HuNoV VLPs, 
GI.1 and GII.4C. GI.1 is derived from a naturally occurring strain of HuNoV GI.1.  
GII.4C is a chimera derived from 3 strains of HuNoV GII.4.  The donor was vaccinated 
on Day 0 and boosted on Day 28 of the trial. Each injection consisted of a dose consisting 
of 5ug of each component VLP. Takeda provided us with three serum time points for this 
particular donor, Day 0, 7, and 21.  Over those time points it was observed that that 
donor’s serum was reactive to both vaccine strains and the polyclonal serum response 
rose after vaccination (Table 1, dataset from Takeda). Three separate serum tests, 
performed by Takeda and their collaborators, Pan-Ig, IgA, and IgG, show that the serum 




polyclonal response blocks GI.1 and GII.4 interactions with their cognate HBGAs at 
roughly the same titer levels as the IgA and IgG response. The carbohydrate assay is a 
proxy for the serums ability to neutralize viral infection as it establishes the serums 
ability to prevent of HuNoV VP1 interactions with HBGA (Reeck et al., 2010).  From 
these assays it is clear that there are antibody species in the polyclonal response that both 
bind and neutralize HuNoV GI.1 and GII.4.  A major goal of this research is to identify 













Rise Titer Fold Rise 
0 1280 1.0 3.133 1.0 4.232 1.0 12.5 1.0 
7 163840 128.0 165.324 52.8 190.921 45.1 589 47.1 
21 655360 512.0 108.143 34.5 368.354 87 638 51.0 













Rise Titer Fold Rise 
0 5120 1.0 10.410 1.0 16.255 1.0 12.5 1.0 
7 40960 8 130.290 12.5 149.295 9.2 82.1 6.6 
21 163840 32 116.114 11.2 364.4 22.4 180.3 14.4 
 







Table 4.1 – Takeda Data from Donor 04NUR001. 
 
Takeda performed assays to detect ELISAs to detect Pan-Ig by ELISA, assay describe 
here (Graham et al., 1994), and IgA and IgG by dissociation-enhanced lanthanide 
fluorescent immunoassay (DELFIA),  assay described (Kavanagh et al., 2011). 
Carbohydrate blocking assays were done to determine neutralization efficiency (Reeck et 
al., 2010). A comprehensive analysis of all donors and time points was described 
(Treanor et al., 2014) . Data is shown from the 3 serum time points processed in this 






We use a sequencing and proteomics approach (Figure 4.1) to identify the serum 
monoclonal antibodies that specifically interact with the vaccine and their relative 
abundance over time points. These approaches allow for the molecular deconvolution of 
the immune response.  PBMC samples from the donor (Day 0, 7, 28, and 56) are used to 
determine the both the VH sequences of the cell repertoire present in circulating B-Cells 
as well as construct a VH:VL paired library that allows use to determine the complete 
variable region composition for an antibody of interest.  Serum samples are processed 
over an antigen column to isolate the antigen specific antibodies. These antibodies are 
trypsinized and processed by LC-MS/MS.  Peptide spectra are mapped against the VH 
sequences to determine which sequences code for the antigen specific peptides. (Lavinder 
et al., 2015), (Lavinder et al., 2014) (Wine et al., 2015), (Wine et al., 2013) 
We find that a single antibody makes ups the majority of the response and over 
100 antibodies are present that are specific to the GII.4C portion of the vaccine.  In 
addition we see that approximately half of the GII.4C specific antibodies are present 
before vaccination and half arose in response to vaccination. Furthermore, amongst the 
top 10 VH sequences of interest, we find 8 of them present in the VH:VL paired data set 





Figure 4.1 – Serum and B-Cell Pipeline  
Antigen specific antibodies are isolated from serum and processed for mass spec.  PBMC 
samples are split in half and processed for VH sequencing and VH:VL sequence pairing.  
The VH libraries are used to build the mass spec libraries and match sequences to unique 
antigen specific peptides.  VH hits from the mass spec analysis are searched against the 
VH:VL databases to determine the full VH and VL sequences of antigen specific 










Prior to thawing cells, cell culture media and cell culture media with DNAse was 
pre-warmed in a 37°C water bath.  Cell culture media is RPMI-1640 (Fisher) and 10% 
Fetal Bovine Serum (FBS). Cell culture media with DNAse is RPMI-1640-10% FBS and 
20 U/ml of DNAse (Roche). Cells were thawed by gently swirly tube by hand in a 37°C 
water bath.  Following thawing, cells were gently transferred to a 50 mL conical.  While 
swirling the conical by hand, 1mL of cell culture media with DNAse was added 
dropwise. Cell culture media with DNAse was continually added and swirled until final 
suspension was 50 mL. Suspension was centrifuged at 300 G for 15 min. at room 
temperature (RT).  Supernatant was removed until only cell pellet and ~500 uL remained. 
3 mL of cell culture media (without DNAse) was added, cells were gently re-suspended, 
and were then incubated in a 37°C water bath for 30 min.  Following incubation, 10 mLs 
of pre-chilled (4°C) FACS buffer (PBS ph7.2, 0.5% BSA, and 2mM EDTA, filter 
sterilized with 0.2 uM filter) was added to cells.  Cell suspension was centrifuged at 300 
G for 5 min at 4°C.  Supernatant was removed and cells were suspended with FACS 
buffer to a final volume of 4 mLs. ½ of the cell sample was used to amplify the VH 
sequences and the other half was processed in order to determine VH:VL repertoire as 
described below. For the former, a portion of PBMCs (~5% of cells) were isolated and 




Fluorescently Activated Cell Sorting (FACS).  For FACS, cells were spun down at 300 G 
for 5 min. and labeled. Labeling consisted of re-suspending cells in 100 uL of FACS 
buffer and adding: 40 uL of anti-CD20-FITC (BD Biosciences), 25 uL of anti-CD38-PE 
(BD Biosciences), 10 uL anti-CD3-PerCP-Cy5.5 (Biolegend), 40 uL anti-CD27-APC 
(BD Biosciences), and 20ul anti-CD19-V450 (BD Biosciences).  Following addition of 
fluorophores, cells were incubated at RT in the dark for at least 20 min. with occasional 
agitation.  Following labeling, cells were spun at 300 G for 5 min. and re-suspended in 1 
mL of FACS buffer. Cells were sorted using an Aria FACS machine (BD-Biosciences).  
CD3-, CD19+, CD27+, CD20+, and CD38- memory B-cells and CD3-, CD19+, CD27+, 
CD20-, and CD38+ Plasma Blast B-cells were isolated. Isolated cells were sorted directly 
into Trizol (Fisher) and stored at -80°C.  
RNA was extracted from the three cell populations (PBMC, Memory and Plasma 
Blasts) using an RNA-easy isolation kit, (Qiagen) and stored in at final volume of 25 uL 
at -80°C. 1st strand cDNA was created according to manufactures protocol using 
Superscript II (Invitrogen), oligo dT primers and 8 uL of RNA. The VH portion of IgM 
and IgG sequences were amplified by PCR with the Faststart High Fidelity PCR system 
(Roche) in seperate PCR reactions. The primer set used was described in (Ippolito et al., 
2012). Each reaction was 500 uL in total volume, 50 uL was used for a negative control 
reaction. 10 uL of cDNA was added to the remaining PCR mixture and the reaction was 
split over 8 PCR tubes.  Thermal cycler conditions were as follows: 1 cycle of 95°C for 2 




min., 55°C for 1 min., 72°C for 1 min.; 26 cycles of 92°C for 1 min., 63 °C for 1 min., 72 
°C for 1 min; and 1 cycle of 72°C for 7 min., followed by a final hold step at 4°C.  PCR 
reactions were run on a 1% agarose gel and the proper bands (~400 bp) were cut out and 




Cells were thawed as described above and ½ were used for VH:VL processing. B-
Cells were isolated from the PBMC population as follows. 15 mL of pre-chilled FACS 
buffer was added to the 2 mL PBMC suspension. Cell suspension was centrifuge at 300 
G for 15 min at 4°C.  Supernatant was removed and cells were gently re-suspended in 
400 uL of pre-chilled FACS buffer. 100 uL Memory B-Cell Biotin-Antibody Cocktail 
(Miltenyi) was added to the cells and incubated at 4°C for 10 min. 300 uL of pre-chilled 
FACS buffer was added and then 200 uL of Anti-Biotin Microbeads (Miltenyi) were 
added.  Suspension was incubated at 4°C for 15 min. Following incubation, 10 mLs of 
pre-chilled FACS buffer was added to the cell suspension.  Cells were then centrifuged at 
300 G for 10 min. at 4°C.  Supernatant was cleared and cells were re-suspended in 500 
uL of pre-chilled FACS buffer.  Cells were then passed through a 70 uM strainer (Fisher).  
After straining, cells were passed through a magnetized LD column (Miltenyi) to remove 
non-B cells from the suspension. 1 mL of pre-chilled FACS buffer was flowed through 




G for 10 min. at 4°C. Supernatant was removed and cells were re-suspended in 1 mL of 
PBS. B-cells were then run through the flow focusing device as described (McDaniel et 
al., 2016).  Briefly, emulsions were created that contain: a single B-cell, reagents to lyse 
the cell, and beads for capturing mRNA.  Following mRNA bead capture, beads were 
isolated and re-emulsified with pairing primer sets, and the reagents for the RT-PCR 
amplification. The primer sets amplify and link VH sequences and VL sequences pairs 
such the the VH and VL from a single B-cell are linked together on the PCR product. 
DNA was purified and paired sequences were amplified by nested PCR to produce 
enough product for Illumina Mi-Seq sequencing.  VH and VL only sequences were also 
amplified from the paired amplicons and submitted for each paired reaction in addition to 
the VH:VL paired amplification. Following sequencing, antibody sequences are 
processed for quality. VH:VL pairs are bio-informatically identified from the data sets 
wherein sequences with ³90% CDRH3 sequence identity are binned into clusters 
(McDaniel et al., 2016).  
Isolation of HuNoV specific antibodies from serum and sample processing for LC-
MS/MS 
 
 An antigen column was set up at each serum time point. HuNoV VLP was added 
to 15 mLs of PBS and buffer exchanged using VivaSpin Turbo 15 10K molecular weight 
cut-off spin tubes (Sartorious), tube were centrifuged at 4000 G at 4°C for ~ 20 min. until 




buffer exchange. Following buffer exchange, 1 mg of VLPs were added to 250 mg of N-
hydroxysuccinimide (NHS)-agarose beads (Thermo).  Prior to VLP addition, NHS-
agarose beads were hydrated with 2.5 mLs of PBS. The bead suspension was rotated end-
over-end at 4°C overnight and then the beads were spun down and washed 2x with PBS. 
Unreacted NHS groups were blocked with 1M ethanolamine, pH 8.3, for 20 min at RT, 
washed with PBS, and packed into a 5 mL column (Thermo). Following column packing, 
conjugated VLPs were washed with 10 column volumes (CV) of 4M Urea in PBS. 
Column was then washed with 20 CVs of PBS. Serum underwent melon gel purification 
according to the manufactures standard protocol (Thermofisher) to isolate serum 
antibodies and remove albumin. Following melon gel purification, serum was run 
through the GII.4C column 5x by gravity flow to capture antigen specific antibodies. The 
column was washed with PBS 2x then washed with water 1x.  Antigen specific 
antibodies were eluted from column with 1 mL of 5% formic acid.  Elution was repeated 
11x for a total of 12 elution fractions. 10 uL of each elution fraction was neutralized with 
100ul of 25x PBS in 2% milk and used in the ELISA step described below to detect 
which fractions contained GII.4C specific antibodies. Elution fractions containing GII.4C 
specific fractions were combined, speed vacuumed to remove formic acid. Samples were 
suspended with 50 ul of water and re-speed vacuumed, this process was repeated 2-3x 
until pH was ~5.5. Following final speed vacuuming, samples were re-suspended into 




The concentrated elution and 50ul from the flow through were processed for mass 
spec. 50 uL of trifluoroethanol was added to each sample. Samples were then reduced by 
adding 5 uL of 110 mM TCEP and incubated in the dark at 55° for 45 min. Then 3 uL of 
550 mM idoacetamide was added and samples incubated for in the dark for 30 min. at RT 
to alkylate the cysteines. 892 uL of 50 mM Tris pH 8 with 2mM CaCl was added to each 
sample.  Samples were then digested with 2 ug of trypsin for 5 hours at 37 degrees to 
produce peptide fragments. The reaction was quenched with 10 uL of 100% formic acid. 
Peptides were then bound to a C18 Hypersep SpinTip (Thermo), washed 3x with 0.1% 
formic acid, eluted with 60% acetonitrile, 0.1% formic acid, and submitted for LC-
MS/MS mass spectrometry processing.   
ELISA 
 
ELISA was performed on all elutions, washes, and pre-flow through serum 
samples and confirmed that the column captured all GII.4C specific antibodies for each 
sample processed.  Wells of the ELISA plate (Costar) were coated with 50 uL of GII.4C 
VLP at 4mg/ml overnight at 4°C.  The next day the plate was washed 3x with 0.05% 
Tween-PBS. Wells were blocked with 5% Milk-PBS for at least 1 hr. at RT and washed 
again. Samples (elutions, flow through, washes, flow through, and melon gel purified 
serum) were incubated for at least 1 hour at RT and then wells were washed.  50ul 1:2000 
Goat anti-human-IgG-HRP (Jackson Immune) was used as the secondary and was 




(Thermo) was added to each well and allowed to develop for 10-20 min.  Reactions were 




Samples were analyzed by liquid chromatography-tandem mass spectrometry on a 
Dionex Ultimate 3000 RSLCnano uHPLC system (Thermo Scientific) coupled to an LTQ 
Orbitrap Velos Pro mass spectrometer (Thermo Scientific). Peptides were first loaded 
onto an Acclaim PepMap RSLC NanoTrap column (Dionex; Thermo Scientific) prior to 
separation on a 75 μm×15 cm Acclaim PepMap RSLC C18 column (Dionex; Thermo 
Scientific) using a 5–40% (v/v) acetonitrile gradient over 250 min at 300 nl/min. Eluting 
peptides were injected directly into the mass spectrometer using a nano-electrospray 
source. The LTQ Orbitrap Velos Pro was operated in data-dependent mode with parent 
ion scans (MS1) collected at 60,000 resolutions. Monoisotopic precursor selection and 
charge state screening were enabled. Ions with charge ≥+2 were selected for collision-
induced dissociation fragmentation spectrum acquisition (MS2) in the ion trap, with a 
maximum of 20 MS2 scans per MS1. Dynamic exclusion was active with a 45-s 
exclusion time for ions selected more than twice in a 30-s window. Each sample was run 





Mass Spec Data Analysis 
 
A database was created using quality processed VH sequences that had ³2 reads. All cell 
types; PBMC, memory, plasma blast, and all time points; Day 0, Day 7, Day 28, and Day 
56, were added to the database. The database was concatenated to a database of 
background proteins comprising of non-donor derived VL sequences (HD1 (Lavinder et 
al., 2014)), a consensus human protein database (Ensemble 73, longest sequence/gene), 
and a list of common protein contaminants (MaxQuant). Donor-specific spectra were 
searched against the corresponding donor-specific database using SEQUEST (Proteome 
Discoverer 1.4, Thermo). Searches considered fully-tryptic peptides only, allowing up to 
two missed cleavages. A precursor mass tolerance of 5 ppm and fragment mass tolerance 
of 0.5 Da were used. Modifications of carbamidomethyl cysteine (static) and oxidized 
methionine (dynamic) were selected. High-confidence peptide-spectrum matches (PSMs) 
were filtered at a false discovery rate of <1% as calculated by Percolator (q-value <0.01, 
Proteome Discoverer 1.4; Thermo Scientific). 
Iso/Leu sequence variants were collapsed into single peptide groups. For each 
scan, PSMs were ranked first by posterior error probability (PEP), then q-value, and 
finally XCorr. Only unambiguous top-ranked PSMs were kept; scans with multiple top-
ranked PSMs (equivalent PEP, q-value, and XCorr) were designated ambiguous 




the previous method (Cox et al., 2011), and the average mass deviation (AMD) for each 
peptide was calculated as described (Boutz et al., 2014) using data from elutions only. 
Peptides with an AMD >1.5 ppm were removed. Additionally, only peptides identified in 
all 3 replicate injections for at least one elution sample were kept as high-confidence 
identifications.  
Peptide abundance was calculated from the extracted-ion chromatogram (XIC) 
peak area, as described (Lavinder et al., 2014), using peak area values generated by the 
Precursor Ions Area Detector node in Proteome Discoverer. For each peptide, a total XIC 
area was calculated as the sum of all unique XIC areas of associated precursor ions and 
the average XIC area across replicate injections was calculated for each sample. For each 
serum time point, peptides were only considered to be antigen specific if they were 
present in all three elution technical replicates and present in none of the three flow-
through technical replicates. 
Clonotype indexing and peptide-to-clonotype mapping   
 
Full-length VH sequences were grouped into clonotypes based on single-linkage 
hierarchical clustering as described(Lavinder et al., 2014). Cluster membership required 
≥90% identity across the CDR-H3 amino sequence as measured by edit distance. High-
confidence peptides identified by MS/MS analysis were mapped to clonotype clusters, 




Clonotype abundance was calculated using only informative peptides mapping to ≥4 
amino acids of the CDR-H3 region, as a sum of XIC areas.   
Quantitating abundances of serum antibodies   
 
Relative abundance of each clonotype was calculated as the sum of XIC areas for 
the clonotype divided by the sum of all XIC areas in that sample. Fraction of serological 
repertoire refers to this relative abundance based on XIC. The amount of each clonotype 
is determined by multiplying its fraction of serological repertoire by the serum titer for 
the same sample.   
Bioinformatics Analysis 
CDRH3s from VH clonotypes identified as antigen specific in the serum analysis 
were used to search for CDRH3s in the VH:VL database by exact match.  VH clonotypes 
and VH:VL sequences were isotyped using an in-house algorithm that searched the 
nucleotide sequence using isotype specific sequences and allowing for up to one mis-
match.  The search sequences used were: IgG-CCTCCACCAAGGGCCCATCGCAG; 
IgM- CCTCCACCAAGGGCCCATCGCAG; and IgA-
CCTCCACCAAGGGCCCATCGCAG.  IgG sequences for somatic hypermutation 
(SHM), CDRH3 length and CDRH3 hydrophobicity measurements were isotyoped from 
their respective time point databases using MiXCR (Bolotin et al., 2015).  SHM was 
calculated by identifying the germline and counting the number of mismatches divided by 




Doolittle hydrophobicity index. Box and whisker plots were built using the tool described 
here (Spitzer et al., 2014). 
 
RESULTS 
Identification of GII.4C specific clonotypes 
A major limitation for developing the specific protocols to this experiment was 
the low volume of serum available from the clinical trial. For the donor analyzed, we 
processed serum samples from Day 0, Day 7, and Day 21 for which we had 2ml, 2ml, 
and 750ul of serum available respectively.  As there was so little serum available we 
sought to focus our efforts on developing optimized processes for the purification of anti-
HuNoV vaccine antibodies from small amounts of serum.  We decided to use the limited 
serum available to determine the repertoire against GII.4C since the GII genogroup is so 
much more prevalent in terms of human infection.  
 
Tryptic peptides from the 3 serum time points, Day 0, Day 7, and Day 21, were 
mapped against the VH clonotype data base. VH clonotypes consist of clusters of VH 
sequences that have 90% amino acid sequence in their CDRH3. A peptide is considered 
clonotype specific if it is unique to that clonotype and covers at least 4 amino acids of the 
CDR3 sequence in the MS/MS analysis. The number of unique GII.4C specific 
clonotypes identified rose in each time point; Day 0 had 57, Day 7 had 72, and Day has 
90.  Overall, when all serum time points are combined, 123 unique GII.4C clonotypes 




Day 21 suggests that 33 clonotypes seen at earlier points are not being induced by the 
vaccine and/or have fallen below the limit of detection (~4 ng/mL, (Wine et al., 2015)). 
The 57 clonotypes identified at Day 0 are considered to be pre-vaccine elicited and likely 
arose from prior natural infections, the rest arose in response to the vaccine. 
The LC peak area (XIC) associated with each clonotype specific peptide was used 
to determine its abundance (Boutz et al., 2014). The XIC for each clonotype was 
calculated by adding the XIC from all of the peptides that map specifically to that 
clonotype. The relative abundance of each clonotype was calculated as the fraction of the 
clonotype XIC over the sum of all of the clonotypes XIC’s in a given time point. The 
relative abundances of each clonotype at each time point are shown in Figure 4.2. 
Clonotypes that account for at least 1% of the overall response are shown in the figure 
4.2 inset. A single clonotype, Clonotype 379, accounted for ~43% of the total response 





Figure 4.2- Relative Clonotype Abundance of GII.4C Specific Antibodies.  
123 clonotypes were identified exclusively in the GII.4C column elution fractions. 
Relative clonotype abundance was calculated by dividing the mass spec peak area (XIC) 
for clonotype specific peptides by the overall sum of mass spec area (XIC) for the entire 
samples. Clonotypes are ranked according to their combined abundance over 3 time 
points. Clonotypes with >1% of total response are shown in the inset. ~50% of 
clonotypes are present in the Day 0 serum indicating that they were present prior to 
vaccination including clonotypes 379, 1431, 309, 15534, 236, 2664, and 2111 in the 
inset. ~50% of clonotypes arose in response to vaccination including clonotypes 618, 







The polyclonal response in the donor’s serum showed an ~20-fold increase in Day 
21 titers compared to Day 0 in both the GII.4C IgG ELISA and Carbohydrate binding 
assays (Table 4.1). In order to determine if the results from the LC-MS/MS analysis 
correspond to the polyclonal result we calculated the abundance of the each clonotype to 
determine how much each one was represented in the response.  Abundance for each 
clonotype at each time point was calculated by multiplying the relative abundance 
(calculated above) by the IgG serum titer for the corresponding time point found in Table 
4.1. The results from this analysis are show in Figure 4.3.  Many of the clonotypes 
identified have abundances that correspond to the serum IgG titer and carbohydrate 
blocking increases both at Day 7 and at Day 21.  However, the abundance of the 
dominant clonotype at Day 21 is far greater, ~135-fold over Day 0, than the polyclonal 
serum data.  This discrepancy suggests that the dominate clonotype may be over 
representative in the LC-MS/MS data or perhaps it is not specific to GII.4C and may have 






Figure 4.3 - Clonotype abundance of GII.4C Specific Antibodies  
Clonotype abundance was calculated by multiplying the relative abundance, shown in 
figure 4.2, by the IgG serum titer at the corresponding time point from Table 4.1.  The 




The VH sequence databases were analyzed to determine aspects related to 
diversity, gene usage and composition.  The number of cells input for each time point 
considered, Day 0, Day 7, Day 28, and Day 56, was relatively consistent over time for 
each time point. The Table 4.2 shows the number of sequences, number of cells, and 




clonotypes for the PBMC from Day 7 is considerably lower than the PBMC clonotypes 
found in the other time points, potentially due to a large expansion of vaccine specific B-
cells that occurs around Day 7 following immune stimulation.  Very few Plasma Blasts 
were recovered from the FACs analysis and interestingly the number of clonotypes 
identified exceeds the number of cells that were collect. This is likely due to over-
sampling of the sequencing reads which increases the likelihood of a clonotype being 
called due to sequencing errors and PCR errors resulting from relatively low amounts of 








Cell Type Productive 
Sequences 
# of Cells Clonotypes 
 
Total IgG IgM 
Day 0 
PBMC 1504013 250000 8590 263 6821 
Memory 220234 26109 5586 140 3230 
Plasma Blast 31428 114 1022 39 561 
Day 7 
PBMC 1350653 250000 1552 307 758 
Memory 232367 22140 5040 184 2790 
Plasma Blast 45472 389 743 64 270 
Day 
28 
PBMC 522314 22000 3049 110 2705 
Memory 152326 26557 4627 133 3566 
Plasma Blast 62883 225 353 59 164 
Day 
56 
PBMC 605972 250000 3169 80 2507 
Memory 181695 16104 2272 ND 1681 
 
Table 4.2 – VH Sequencing and Clonotypes.  
3 cell types were collected from each time point and VH’s were processed for deep 
sequencing.  A productive sequence has undergone quality processing, contains an 
antibody sequences, has no stop codons, and has an identifiable CDRH3. Clonotypes 
consist of sequences that have 90% CDRH3 sequence identity to one another. IgG and 
IgM were identified by searching for a constant region specific nucleotide sequence and 






The IgG clusters from the VH libraries from each time point (Day 0, Day 7, Day 
28, and Day 56) as well as the GII.4C specific clonotypes were analyzed for different 
characteristics related to gene usage and their CDR3 regions. The time point data sets 
contain the VH data from all three cell types analyzed, PBMC, Memory, and Plasma 
Blasts. V-gene usage was calculated for each V-Gene family (Figure 4.4). V-Gene usage 
is fairly consistent over the 4 time points as well.  In the GII.4C specific clonotypes, the 
V-gene usage mirrors the time point usage in the majority of V-genes.  However, there 
are 6 V-genes in which the fraction of GII.4C specific clonotypes ³3x the amount seen in 
the time point data sets.  This suggests that V-genes; IGHV1-17, IGHV1-45, IGHV3-38, 
IGHV3-43, IGHV3-66, and IGHV4-4, code for antibody germlines predisposed to 








Figure 4.4 V-gene usage of IgG sequences time point and GII.4C specific clonotype data 
sets  
V gene usage was calculated for each V-gene family.  Each time point data set analyzed 
was composed of IgG isotypes from the VH sequence database from all three cell type 
processed at that time point.  The GII.4C specific data set contains the clonotypes 
identified in the serum analysis. 
 
CDRH3 composition can be informative as the CDRH3 peptide is usually found 
in the middle of the antigen binding site and typically contributes to the majority of the 
antigen binding. CDRH3 lengths for IgG clusters from each of the VH time point 




length of the IgG coding cells does not vary over time and the GII.4C specific CDRH3 
lengths are also consistent with the time point specific data (Figure 4.5).  CDRH3 
hydrophobicity was also determined, it was calculated using the Kyte-Doolittle 
hydrophobicity index.  Average CDRH3 Hydrophobicity score was ~ -0.5 over all time 
points and the GII.4C specific clonotypes (Figure 4.6).  
  
 
Figure 4.5 - CDR3 Length across time points and GII.4C specific clonotypes  
CDR3 lengths were calculated for each time point and for GII.4C specific clonotypes.  
Time point data sets include all identified IgG clusters from all cell types (PBMCs, 
Memory, and Plasma Blasts). The GII.4C specific clonotypes include all of the 
clonotypes identified in the elution specific fraction identified over the three serum 






Figure 4.6 - CDR3 Hydrophobicity across time points and GII.4C specific clonotypes  
CDR3 Hydrophobicity was calculated for each time point and for GII.4C specific 
clonotypes.  Time point data sets include all identified IgG clusters from all cell types 
(PBMCs, Memory, and Plasma Blasts.)  The GII.4C specific clonotypes include all of the 
clonotypes identified in the elution specific fraction identified over the three serum 
timepoints, Day 0, 7, and 21. 
 
The somatic hypermuation (SHM) rate was calculated for the VH IgG sequence 
time points and the GII.4C specific clonotypes (Figure 4.7).  SHM measures how many 
mutations have been made to a VH germ line sequence and are a measure of how much 
affinity maturation an antibody has undergone.  When comparing the 4 different time 
points, Day 7 has the highest SHM rate, the media SHM rate is 8 amino acid changes per 
VH.  The SHM rate decreases over the final two time points (Day 28 and Day 56).  The 
GII.4C has a median SHM rate of 9.4 amino acid changes per VH as would be expected 
by a set of antibody sequences that bind antigen and have been selected by the immune 







Figure 2.7 – Somatic hypermutation across time points and GII.4C specific clonotypes  
Time point data sets include all identified IgG clusters from all cell types (PBMCs, 
Memory, and Plasma Blasts.  The GII.4C specific clonotypes include all of the 
clonotypes identified in the elution specific fraction identified over the three serum 
timepoints, Day 0, 7, and 21. Somatic hypermutation was calculated as the number of 
mutations divided by the length of the germline sequence. 
 
VH:VL Pairing Results 
 
VH:VL paired sequences were clustered and isotyped. Table 4.3 shows the 
number of sequences, number of cells, and clonotypes derived from the VH:VL data sets 
for each cell time point. The number of clusters and isotypes is considerably lower than 
what was identified in the VH only database as the pairing process in inherently less 











# of Cells Clusters 
 
Total IgG IgA IgM 
Day 0 1058236 115000 570 55 49 379 








408 11 17 361 
 
Table 4.3 – VH:VL Sequencing and clonotypes.  
B-Cells were isolated from each time point and processed for VH:VL pairing. A 
productive VH:VL sequence pair is one that has undergone quality processing, contains a 
pair of identifiable antibody sequences that each contain a CDR3, and the pair consists of 
a VH and VL.  To identify a cluster, sequences were sorted by most frequent CDRH3, the 
most abundant was seeded as the first cluster, if the following sequences had a 90% 
identical CDRH3 they were added to the cluster, if not they became the seed for the new 
cluster.  IgG, IgA, and IgM were identified by searching for a constant region specific 
nucleotide sequence and allowing for one mismatch. 
 
The CDRH3 amino acid sequences from the top GII.4C specific clonotypes 
identified in the LC-MS/MS analysis were searched against the CDRH3s identified 
VH:VL pairing databases from Days 0, 7, 28, and 56. CDRH3s from 8 of the top 10 
clonotypes identified in the mass spec data were also identified by exact match to CDR3s 
in the paired databases (Table 4.4). The efficiency quickly dropped off as only 13 of the 
top 60 GII.4C clonotypes were identified in the paired databases. Nearly all of the 
corresponding VH:VL pairs were identified in the Day 7 paired data set.  The top GII.4C 
specific CDR3s that were identified in the paired data bases are highly ranked within the 




with nearly all of them in the top 20% of paired clusters, indicating that the most 


























379 ARDYWNYHIRGWYPDY QQSDSTPYT Day 7 
1431 ARDGPRPDGTGYAGPSNDY QHRSSWPALT Day 7 
618 TRDQCGGDCSDF QQSHSAPLT Day 7 
273 ARAVPLLGELSIRLSTFDN AAWDDSLGAWV Day 7 
309 ARSPRTVAIKPYYFDY QQYEDLPPT Day 0 
174 AGRASGSSPPH QVYGSSQT Day 7 
236 AGHRGYSSGWPLDY QQRTNWPPGVT Day 7 
234 ARDRPLASGWDRDDYYGMDV QQANGPNGPLT Day 7, 56 
165 ARAGIIHAINGFDI NSYTGGGALV Day 7 
3423 ARGTIYDFLAGDRGLGF QQYYSSPPD Day 7, 56 
1227 AKDKTRTLRLGYSGMDV QQSFSTPRT Day 7, 56 
178 ATGRVSSSWYRHEYIHH HQYYTTPYT Day 7 
5855 AKDINFGGDTEVIKMGWFDL QQYASSPPLT Day 7 
131 ARFPSAGYGMDV LQSYGAPSFT Day 7 
 
Table 4.4 – GII.4C specific clonotypes identified in paired datasets.  
14 clonotypes from the GII.4C specific data set were identified in the paired data sets.  
The top 8 in this table were found in the top 10 most abundant clonotypes as determined 
by LC-MS/MS (see inset in Figure 4.2).  Heavy chain and light chain CDR3 pairs are 
listed.  The time point identified in refers to the paired dataset time point the VH:VL 
CDR3 pairs were identified in. Underlined sequences have been selected for monoclonal 






ONGOING WORK AND DISCUSSION 
  
Currently we are working on expressing, purifying and characterizing 8 of the 
paired data sequences identified (underlined in Table 4.4). In addition to exact CDR3 
matches, the selected sequences had the best mass spec coverage when analyzing for non-
CDRH3 peptides (CDR1, CDR2, SHMs).  Monoclonals will be screened for binding 
activity to both HuNoV GI.1 and GII.4C VLPs as well as VLPs from other Norovirus 
strains.  Monoclonals will also be screened in the carbohydrate assay for their ability to 
block viral interactions with their cognate HBGA sugar groups.  Epitope mapping will be 
performed to identify which portion of the virus and the vaccine are eliciting the immune 
response. Samples from two additional donors have been processed and analysis is 
underway. 
 Prior to this study it was clear that this donor had a modest polyclonal response 
that contains antibodies that both bind and block HuNorV.  However, composition and 
make-up of the poly clonal response was unclear. Using two pipelines to analyze both the 
serum antibody repertoire and the B-Cell VH sequences we have identified antibody 
sequences that are specific to the GII.4C VLP portion of a candidate Norovirus vaccine.  
We have identified over 100 clonotypes that are specific to the GII.4C VLP.  Nearly half 
of the clonotypes that interact with the vaccine were present in the donor prior to 





 Time course data on the molecular composition and cellular response gleaned 
from this donor and others inform the vaccine development process.  CDRH3 analysis 
and V-gene usage highlights aspects of the immune system that contribute to combating 
HuNoV. Monoclonal antibodies identified by this approach can be characterized with 
respect to binding affinity, ability to block infection, and which epitopes on the virus the 
bind too.  Furthermore, analysis of additional donors will shed light on how universal the 
response mechanisms to the virus is. 
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